Risk Assessment and Risk Management Plan for

**DIR 204**

Limited and controlled release of wheat genetically modified for increased tolerance to environmental stress

Applicant: Trigall Australia Pty Ltd

August 2024

# Summary of the Risk Assessment and Risk Management Plan

**for**

**Licence Application No. DIR 204**

## Decision

The Gene Technology Regulator (the Regulator) has decided to issue a licence for this application for the intentional release of a genetically modified organism (GMO) into the environment. A Risk Assessment and Risk Management Plan (RARMP) for this application has been prepared by the Regulator in accordance with the *Gene Technology Act 2000* (the Act) and corresponding state and territory legislation, and finalised following consultation with a wide range of experts, agencies and authorities, and the public. The RARMP concluded that the proposed field trial poses negligible risk to human health and safety and the environment and that any risks posed by the dealings can be managed by imposing conditions on the release.

## The application

|  |  |
| --- | --- |
| *Project Title* | Limited and controlled release of wheat genetically modified for increased tolerance to environmental stress |
| *Applicant* | Trigall Australia Pty Ltd |
| *Parent organism* | Wheat (*Triticum aestivum* L.) |
| ***Genetic modifications*** | |
| Introduced genes and modified traits | * *HaHB4* gene from *Helianthus annuus* conferring environmental stress tolerance * *bar* gene from *Streptomyces hygroscopicus* as a selectable marker gene conferring glufosinate herbicide tolerance |
| Genetic modification method | Biolistic transformation |
| Unique identifier of GMO | IND-ØØ412-7 |
| Trade name of GMO | HB4 wheat |
| *Principal purpose* | To gather research and regulatory data for HB4 wheat under Australian growing conditions, including under environmental stress |
| *Previous releases* | HB4 wheat is approved for commercial cultivation in Argentina, Brazil and Paraguay |
| ***Proposed limits*** | |
| Proposed use of GM plants | No use in human food or animal feed |
| Proposed location/s | Up to 10 sites per year in wheat growing areas of New South Wales, Victoria, Western Australia and South Australia |
| Proposed release size | Up to 20 hectares per year in total |
| Proposed period of release | From issue of licence until December 2029 |

## Risk assessment

The risk assessment process considers how the genetic modification and proposed activities conducted with the GMOs might lead to harm to people or the environment. Risks are characterised in relation to both the seriousness and likelihood of harm, taking into account current scientific/technical knowledge, information in the application (including proposed limits and controls) and relevant previous approvals. Both short- and long-term risks are considered.

Credible pathways to potential harm that were considered included exposure of people or animals to the GM plant material, potential for persistence or dispersal of the GMOs, and transfer of the introduced genetic material to non-GM plants. Potential harms associated with these pathways included adverse health effects in people or animals, and environmental harms due to weediness.

The risk assessment concludes that risks to the health and safety of people or the environment from the proposed dealings are negligible. The principal reasons for the conclusion of negligible risks are that the proposed limits and controls will effectively minimise exposure to the GMOs. In addition, there is no evidence to suggest the introduced genetic modifications could lead to harm to people or the environment.

## Risk management plan

The risk management plan describes measures to protect the health and safety of people and to protect the environment by controlling or mitigating risk. The risk management plan is given effect through licence conditions.

As the level of risk is considered negligible, specific risk treatment is not required. However, since this is a limited and controlled release, the licence includes limits on the size, locations and duration of the release, as well as controls to prohibit the use of GM plant material in human food and animal feed, to minimise dispersal of the GMOs or GM pollen from the trial sites, to transport GMOs in accordance with the Regulator’s guidelines, to destroy the GMOs at the end of the trial and to conduct post-harvest monitoring at the trial sites to ensure the GMOs are destroyed.

Table of contents

[Summary of the Risk Assessment and Risk Management Plan I](#_Toc174708892)

[Decision I](#_Toc174708893)

[The application I](#_Toc174708894)

[Risk assessment II](#_Toc174708895)

[Risk management plan II](#_Toc174708896)

[Table of contents III](#_Toc174708897)

[Abbreviations V](#_Toc174708898)

[Chapter 1 Risk assessment context 1](#_Toc174708899)

[Section 1 Background 1](#_Toc174708900)

[1.1 Interface with other regulatory schemes 2](#_Toc174708901)

[Section 2 The proposed dealings 2](#_Toc174708902)

[2.1 The proposed limits of the trial (duration, size, locations and people) 2](#_Toc174708903)

[2.2 The proposed controls to restrict the spread and persistence of the GMOs 4](#_Toc174708904)

[Section 3 The parent organism 5](#_Toc174708905)

[Section 4 The GMOs, nature and effect of the genetic modification 6](#_Toc174708906)

[4.1 Introduction to the GMOs 6](#_Toc174708907)

[4.2 Method of genetic modification 6](#_Toc174708908)

[4.3 The introduced genes and encoded proteins 8](#_Toc174708909)

[4.4 Potential adverse health effects of the GM wheat 9](#_Toc174708910)

[4.5 Characterisation of the GMOs 10](#_Toc174708911)

[Section 5 The receiving environment 10](#_Toc174708912)

[5.1 Relevant abiotic factors 10](#_Toc174708913)

[5.2 Relevant biotic factors 10](#_Toc174708914)

[5.3 Relevant agricultural practices 11](#_Toc174708915)

[5.4 Presence of related plants in the receiving environment 11](#_Toc174708916)

[5.5 Presence of similar genes and encoded proteins in the environment 11](#_Toc174708917)

[Section 6 Relevant Australian and international approvals 11](#_Toc174708918)

[6.1 Australian approvals 11](#_Toc174708919)

[6.2 International approvals 12](#_Toc174708920)

[Chapter 2 Risk assessment 13](#_Toc174708921)

[Section 1 Introduction 13](#_Toc174708922)

[Section 2 Risk identification 14](#_Toc174708923)

[2.1 Risk source 14](#_Toc174708924)

[2.2 Causal pathway 15](#_Toc174708925)

[2.3 Potential harm 15](#_Toc174708926)

[2.4 Postulated risk scenarios 16](#_Toc174708927)

[2.5 Risk scenario 1 17](#_Toc174708928)

[2.6 Risk scenario 2 19](#_Toc174708929)

[2.7 Risk scenario 3 21](#_Toc174708930)

[Section 3 Uncertainty 23](#_Toc174708931)

[Section 4 Risk evaluation 24](#_Toc174708932)

[Chapter 3 Risk management plan 25](#_Toc174708933)

[Section 1 Background 25](#_Toc174708934)

[Section 2 Risk treatment measures for substantive risks 25](#_Toc174708935)

[Section 3 General risk management 25](#_Toc174708936)

[3.1 Limits and controls on the release 25](#_Toc174708937)

[3.2 Other risk management considerations 29](#_Toc174708938)

[Section 4 Issues to be addressed for future releases 30](#_Toc174708939)

[Section 5 Conclusions of the RARMP 30](#_Toc174708940)

[References 32](#_Toc174708941)

[Appendix A: Summary of submissions from prescribed experts, agencies and authorities on the consultation RARMP 35](#_Toc174708942)

[Appendix B: Summary of submissions from the public on the consultation RARMP 38](#_Toc174708943)

Abbreviations

|  |  |
| --- | --- |
| APVMA | Australian Pesticides and Veterinary Medicines Authority |
| cm | centimetre |
| DIR | Dealings involving Intentional Release |
| DNA | deoxyribonucleic acid |
| ELISA | enzyme-linked immunosorbent assay |
| FSANZ | Food Standards Australia New Zealand |
| GM | genetically modified |
| GMO | genetically modified organism |
| ha | hectare |
| HGT | horizontal gene transfer |
| IBC | Institutional Biosafety Committee |
| LC-MS | liquid chromatography–mass spectrometry |
| m | metre |
| NSW | New South Wales |
| OECD | Organisation for Economic Co-operation and Development |
| OGTR | Office of the Gene Technology Regulator |
| PAT | phosphinothricin N-acetyltransferase |
| RARMP | Risk Assessment and Risk Management Plan |
| Regulations | Gene Technology Regulations 2001 |
| Regulator | Gene Technology Regulator |
| SA | South Australia |
| the Act | *Gene Technology Act 2000* |
| WA | Western Australia |

1. Risk assessment context
   1. Background
2. An application has been made under the *Gene Technology Act 2000* (the Act) for Dealings involving the Intentional Release (DIR) of genetically modified organisms (GMOs) into the Australian environment.
3. The Act and the Gene Technology Regulations 2001 (the Regulations), together with corresponding State and Territory legislation, comprise Australia’s national regulatory system for gene technology. Its objective is to protect the health and safety of people, and to protect the environment, by identifying risks posed by or as a result of gene technology, and by managing those risks through regulating certain dealings with GMOs.
4. Section 50 of the Act requires that the Gene Technology Regulator (the Regulator) must prepare a Risk Assessment and Risk Management Plan (RARMP) in response to an application for release of GMOs into the Australian environment. Sections 50, 50A and 51 of the Act and Sections 9 and 10 of the Regulations outline the matters which the Regulator must take into account and who must be consulted when preparing the RARMP.
5. The *Risk Analysis Framework* ([OGTR, 2013](#_ENREF_32)) explains the Regulator‘s approach to the preparation of RARMPs in accordance with the Act and the Regulations. The Regulator has also developed operational policies and guidelines that are relevant to DIR licences. These documents are available from the Office of the Gene Technology Regulator (OGTR) [website](https://www.ogtr.gov.au/resources).
6. Figure 1 shows the information that is considered, within the regulatory framework above, in establishing the risk assessment context. This information is specific for each application. Risks to the health and safety of people or the environment posed by the proposed release are assessed within this context. Chapter 1 provides the specific information for establishing the risk assessment context for this application.



**Figure 1. Summary of parameters used to establish the risk assessment context, within the legislative requirements, operational policies and guidelines of the OGTR and the Risk Analysis Framework.**

1. In accordance with Section 50A of the Act, this application is considered to be a limited and controlled release application, as the Regulator was satisfied that it meets the criteria prescribed by the Act. Therefore, the Regulator was not required to consult with prescribed experts, agencies and authorities before preparation of the RARMP.
2. Section 52 of the Act requires the Regulator to seek comment on the RARMP from agencies - the Gene Technology Technical Advisory Committee (GTTAC), State and Territory Governments, Australian Government authorities or agencies prescribed in the Regulations, Australian local councils and the Minister for the Environment - and from the public. The advice from the prescribed experts, agencies and authorities and how it was taken into account is summarised in Appendix A. Eight public submissions were received and their consideration is summarised in Appendix B.
   * 1. Interface with other regulatory schemes
3. Gene technology legislation operates in conjunction with other regulatory schemes in Australia. The GMOs and any proposed dealings may also be subject to regulation by other Australian government agencies that regulate GMOs or GM products, including Food Standards Australia New Zealand (FSANZ), the Australian Pesticides and Veterinary Medicines Authority (APVMA), the Therapeutic Goods Administration, the Australian Industrial Chemicals Introduction Scheme and the Department of Agriculture, Fisheries and Forestry. These dealings may also be subject to the operation of State legislation recognising an area as designated for the purpose of preserving the identity of GM crops, non-GM crops, or both GM crops and non-GM crops, for marketing purposes.
4. To avoid duplication of regulatory oversight, risks that have been considered by other regulatory agencies will not be re-assessed by the Regulator.
   1. The proposed dealings
5. Trigall Australia Pty Ltd (the applicant, Trigall Australia) proposes to release wheat genetically modified for increased tolerance to environmental stress. The GM wheat has the OECD unique identifier IND-ØØ412-7. Its trade name is HB4 wheat.
6. The purpose of the proposed field trial is to evaluate HB4 wheat under Australian growing conditions, including under environmental stress. The trial will gather research and regulatory data regarding agronomic performance, environmental stress tolerance, nutritional assessment, compositional analysis, molecular analysis, and genetic stability. Some experiments may involve milling GM wheat grains into flour.
7. The dealings involved in the proposed intentional release are to:

* conduct experiments with the GMOs
* breed the GMOs
* propagate the GMOs
* grow the GMOs
* use the GMOs in the course of manufacture of a thing that is not a GMO
* import the GMOs
* transport the GMOs
* dispose of the GMOs

and possess, supply or use the GMOs in the course of any of these dealing*s.*

* + 1. The proposed limits of the trial (duration, size, locations and people)

1. The field trial is proposed to take place from issue of the licence until December 2029. This period would cover 5 winter planting seasons and 5 summer planting seasons. The GM wheat would be grown primarily as a winter crop, but occasionally a summer crop cycle may be grown.
2. The GM wheat would be grown on up to 10 trial sites per year, with an area of up to 2 ha per site. The maximum combined planting area would be 20 ha per year.
3. The trial sites would be selected from 135 possible local government areas (LGAs) in New South Wales (NSW), Victoria, Western Australia (WA) and South Australia (SA) (Table 1). The field trials would occur on sites owned by the applicant or on private land in rural areas.


**Table 1. LGAs where GM wheat trial sites may be located**

| **NSW** | **Victoria** | **WA** | **SA** |
| --- | --- | --- | --- |
| Berrigan | Ararat | Albany | Adelaide Plains |
| Bland | Ballarat | Beverley | Barossa |
| Blayney | Benalla | Boddington | Light |
| Cabonne | Buloke | Boyup Brook | Wakefield |
| Coolamon | Campaspe | Bridgetown-Greenbushes |  |
| Coonamble | Central Goldfields | Brookton |  |
| Cootamundra-Gundagai | Colac Otway | Broomehill-Tambellup |  |
| Cowra | Corangamite | Carnamah |  |
| Dubbo | Gannawarra | Coorow |  |
| Edward River | Glenelg | Corrigin |  |
| Federation | Golden Plains | Cranbrook |  |
| Forbes | Greater Bendigo | Cuballing |  |
| Gilgandra | Greater Geelong | Cunderdin |  |
| Greater Hume | Greater Shepparton | Dalwallinu |  |
| Griffith | Hepburn | Denmark |  |
| Gunnedah | Hindmarsh | Donnybrook-Balingup |  |
| Gwydir | Horsham | Dowerin |  |
| Hay | Indigo | Dumbleyung |  |
| Hilltops | Loddon | Esperance |  |
| Inverell | Macedon Ranges | Gnowangerup |  |
| Junee | Mildura | Goomalling |  |
| Leeton | Mitchell | Greater Geraldton |  |
| Liverpool Plains | Moira | Jerramungup |  |
| Lockhart | Moorabool | Katanning |  |
| Mid-Western | Mount Alexander | Kent |  |
| Moree Plains | Moyne | Kojonup |  |
| Murray River | Northern Grampians | Manjimup |  |
| Murrumbidgee | Pyrenees | Merredin |  |
| Muswellbrook | Southern Grampians | Mingenew |  |
| Narrabri | Strathbogie | Moora |  |
| Narrandera | Swan Hill | Morawa |  |
| Narromine | Wangaratta | Nannup |  |
| Orange | West Wimmera | Narrogin |  |
| Parkes | Wodonga | Northam |  |
| Snowy Valleys | Wyndham | Perenjori |  |
| Tamworth | Yarriambiack | Pingelly |  |
| Temora |  | Plantagenet |  |
| Upper Hunter |  | Quairading |  |
| Wagga Wagga |  | Ravensthorpe |  |
| Walgett |  | Tammim |  |
| Warren |  | Three Springs |  |
| Warrumbungle |  | Toodyay |  |
| Weddin |  | Victoria Plains |  |
|  |  | Wagin |  |
|  |  | Wandering |  |
|  |  | West Arthur |  |
|  |  | Wickepin |  |
|  |  | Williams |  |
|  |  | Wongan-Ballidu |  |
|  |  | Woodanilling |  |
|  |  | Wyalkatchem |  |
|  |  | York |  |

1. Only trained and authorised persons would be permitted to deal with the GM wheat.
   * 1. The proposed controls to restrict the spread and persistence of the GMOs
2. The applicant has proposed a number of controls to restrict the spread and persistence of the GM wheat and the introduced genetic material in the environment. These include:

* locating each trial site at least 50 m away from the nearest natural waterway
* only permitting authorised persons to access the trial sites
* surrounding each planting area with a 10 m monitoring zone and a 50 m inspection zone that are inspected while the GMOs are flowering to destroy any wheat or sexually compatible plants
* surrounding each inspection zone with a 140 m isolation zone where no wheat or sexually compatible plants are grown
* treating non-GM wheat plants grown on the trial sites as if they are GMOs
* inspecting and cleaning all equipment used on trial sites prior to use for any other purpose
* controlling rodents on trial sites
* cleaning of planting areas post-harvest
* monitoring each post-harvest planting area for volunteers for two years, inspecting every 55 days, and destroying any volunteers found
* tilling and irrigating each planting area during the post-harvest monitoring period
* transporting and storing GMOs in accordance with the current Regulator's [Guidelines for the Transport, Storage and Disposal of GMOs](https://www.ogtr.gov.au/resources/publications/guidelines-transport-storage-and-disposal-gmos)
* destroying all GMOs from the trial not required for testing or future planting
* not engaging personnel who have a known allergy to wheat to work with the GM wheat
* not allowing the GMOs or GM products to be used for human food or animal feed.

1. Figure 2 shows the trial site layout proposed by the applicant.



**Figure 2. Schematic diagram (not to scale) of proposed trial site layout. Each trial site may include one or multiple planting areas.**

1. The proposed limits and controls are taken into account in the risk assessment (Chapter 2) and their suitability for containing the release will be evaluated in the risk management plan (Chapter 3).
   1. The parent organism
2. The parent organism of the GMOs is *Triticum aestivum* L. The terms ‘wheat’ and ‘bread wheat’ will be used as general terms to refer to *T. aestivum* throughout this document. The other wheat species grown in Australia is *Triticum turgidum* subsp. *durum* (Desf.) Husn., also known as durum or pasta wheat.
3. Detailed information about the parent organism is contained in the reference document produced to inform the risk analysis process for licence applications involving GM wheat: *The Biology of* Triticum aestivum *L. (Bread Wheat)* ([OGTR, 2021](#_ENREF_33)). This document is available from the [Resources page](https://www.ogtr.gov.au/resources?f%5B0%5D=h_publication_type%3A58) on the OGTR website. Baseline information from this document will be used and referred to throughout the RARMP.
4. Wheat is Australia’s largest agricultural crop, with over 12 million hectares of wheat planted in Australia in 2023 ([ABARES, 2023](#_ENREF_1)). Commercial wheat is cultivated in the ‘wheat belt’ from south-eastern Queensland through NSW, Victoria, Tasmania, southern SA and southern WA. The major uses of wheat grown in Australia are as either a grain crop for human consumption or a feed grain for livestock ([AEGIC, 2020](#_ENREF_2)).
5. Wheat is exotic to Australia, but is present outside cultivation in all states and territories of Australia ([Atlas of Living Australia website](https://www.ala.org.au/), accessed 4 March 2024). Wheat is not a weed of national significance or a declared weed in any state or territory ([Weeds Australia website](https://weeds.org.au/overview/lists-strategies/), accessed 4 March 2024). A weed risk assessment for wheat by the OGTR found that wheat possesses few weedy attributes ([OGTR, 2021](#_ENREF_33)). Similarly, a weed risk assessment of wheat by the Victorian government placed wheat in the lowest weed risk ranking category ([White et al., 2022](#_ENREF_45)).
6. Wheat contains a number of allergens. Allergic responses can occur in susceptible individuals due to ingestion of food containing wheat, inhalation of wheat flour, inhalation of wheat pollen, or skin contact with wheat proteins ([Stobnicka and Gorny, 2015](#_ENREF_40); [Quirce et al., 2016](#_ENREF_35); [Venter et al., 2016](#_ENREF_43)). Ingestion of food containing wheat can also cause adverse health effects in people with coeliac disease, which is an autoimmune response triggered by gluten in wheat grain, or in people with non-coeliac wheat sensitivity ([Rej et al., 2020](#_ENREF_36)).
   1. The GMOs, nature and effect of the genetic modification
      1. Introduction to the GMOs
7. The GM wheat is known by the trade name HB4 wheat or by the OECD unique event identifier IND‑ØØ412-7. It contains two introduced genes, which are described in Table 2.

**Table 2. Introduced genes in HB4 wheat**

|  |  |  |
| --- | --- | --- |
| **Gene** | **Source organism** | **Function** |
| *HaHB4* | Sunflower (*Helianthus annuus*) | Encodes transcription factor conferring environmental stress tolerance |
| *bar* | *Streptomyces hygroscopicus* | Selectable marker gene conferring glufosinate herbicide tolerance |

1. The expression of the introduced genes is controlled by introduced regulatory sequences, which are listed in Table 3. As the 2 introduced genes both have a strong constitutive promoter, the introduced genes are expected to be expressed in all GM wheat plant tissues.

Table 3. Introduced regulatory sequences in HB4 wheat

| **Genetic element** | **Source organism** | **Function** |
| --- | --- | --- |
| *ubi1* (ubiquitin) promoter | Maize (*Zea mays*) | Constitutive promoter |
| *ubi1* 5’ untranslated exon | Maize (*Z. mays*) | Enhance transgene expression |
| *ubi1* first intron | Maize (*Z. mays*) | Enhance transgene expression |
| *nos* terminator | *Agrobacterium tumefaciens* | Terminator |

* + 1. Method of genetic modification

1. HB4 wheat was generated by biolistic transformation. Information about this method can be found in the document [Methods of plant genetic modification](https://www.ogtr.gov.au/resources/publications/risk-assessment-reference-methods-plant-genetic-modification), available from the OGTR Risk Assessment References page. The parental wheat variety was co-transformed with plasmids *pIND4‑HB4* and *pIND4-Bar.* Plasmid maps of these two plasmids are shown in Figure 3.



**Figure 3. Plasmid maps of plasmids pIND-HB4 and pIND4-Bar. Supplied by applicant.**

1. Trigall Genetics (the parent company of Trigall Australia) characterised the genetic modification in HB4 wheat using Southern blotting and genomic sequencing ([Trigall Genetics, 2021](#_ENREF_42)). The GM wheat was found to contain two complex DNA insertions in a single genetic locus. The insertions included multiple intact or partial copies of transgenes (Table 4). The insertions have not interrupted any known endogenous wheat genes.

Table 4. Gene copy numbers in HB4 wheat

| **Gene** | **Total copies** | **Intact copies** | **Intact copies with functional regulatory elements** |
| --- | --- | --- | --- |
| *HaHB4* | 3 | 2 | 1 |
| *bar* | 8 | 7 | 3 |
| *bla* | 19 | 12 | 0 |
| *gus* | 4 | 0 | 0 |

1. As shown in Table 4, HB4 wheat contains copies of two intentionally introduced gene sequences (*HaHB4* and *bar*) and two unintentionally introduced gene sequences (*bla* and *gus*). The *bla* gene is part of the plasmid backbone of both *pIND4 HB4* and *pIND4-Bar*. It is an *Escherichia coli* gene that encodes the β‑lactamase protein conferring ampicillin antibiotic resistance, used as a selectable marker gene for plasmid-carrying bacteria. The *gus* gene apparently originated from a third plasmid that was not intentionally used for transformation but was present during the transformation process. The *gus* gene is an *E. coli* gene encoding the β-glucuronidase enzyme, used as a visual marker to monitor the efficiency of transformation ([Trigall Genetics, 2021](#_ENREF_42)).
2. The *bla* gene is under the control of a bacterial promoter that would not function in plants. Therefore, the *bla* gene is not expected to be expressed in HB4 wheat.
3. There are no intact copies of the *gus* gene in HB4 wheat, and none of the partial copies have intact promoter sequences. Therefore, the *gus* gene is not expected to be expressed in HB4 wheat.
4. HB4 wheat contains one *HaHB4* gene copy and 3 *bar* gene copies with complete regulatory sequences (Table 4). ELISA and LC-MS techniques confirmed that the *HaHB4* and *bar* genes are expressed in the GM wheat ([Trigall Genetics, 2021](#_ENREF_42)).
   * 1. The introduced genes and encoded proteins

##### *HaHB4*

1. The sunflower *HaHB4* gene encodes the transcription factor Hahb-4 (*Helianthus annuus* homeobox-4). The *HaHB4* gene was found to be expressed at very low levels in sunflower plants grown under normal conditions. *HaHB4* expression was strongly induced by drought stress and moderately induced by salt stress, but was not detectably induced by cold stress or heat stress ([Gago et al., 2002](#_ENREF_11)).
2. GM *Arabidopsis thaliana* plants that constitutively express *HaHB4* were generated. The GM plants had a phenotype of reduced height, smaller leaves and delayed flowering, but no reduction in seed production, in comparison to wild-type plants. Under mild water deficit conditions, wild-type plants wilted, but GM plants expressing *HaHB4* were unaffected. Under severe water deficit conditions, only 9% of wild-type plants survived, but 73% of GM plants survived ([Dezar et al., 2005b](#_ENREF_9)).
3. Overexpression of the *HaHB4* gene induces a wide range of changes in the Arabidopsis transcriptome, with significant increases or decreases to the level of transcription of 815 genes. The proposed mechanism for drought stress tolerance observed in transgenic plants expressing *HaHB4* is related to inhibition of leaf senescence ([Manavella et al., 2006](#_ENREF_26)).
4. *HaHB4* expression in sunflower was also reported to be induced by mechanical damage or caterpillar feeding activity. GM Arabidopsis and maize plants that constitutively express *HaHB4* demonstrated upregulation of herbivory defence genes and reduced feeding activity by caterpillars in comparison to wild-type plants ([Manavella et al., 2008](#_ENREF_27)).
5. In the GM wheat, the *HaHB4* gene is expected to confer increased tolerance to environmental stresses, including drought stress, salt stress and biotic stress from invertebrate feeding, to protect crop yield.

##### *bar*

1. The *bar* (bialaphos resistance) gene was isolated from *S. hygroscopicus* ([Thompson et al., 1987](#_ENREF_41)). It encodes a phosphinothricin acetyltransferase (PAT) enzyme that confers tolerance to glufosinate herbicide. PAT acetylates glufosinate, converting it to *N*-acetyl-L-glufosinate which is not toxic to plants ([OECD, 2002](#_ENREF_30)).
2. The Regulator has previously assessed and approved GM crops containing the *bar* gene for commercial release in Australia, most recently under licence [DIR 190](https://www.ogtr.gov.au/gmo-dealings/dealings-involving-intentional-release/dir-190).
3. The applicant intends to use the *bar* gene as a selectable marker gene during breeding of the GM wheat. A half dose of glufosinate herbicide will be applied to plants to identify null segregants that do not contain the GM event. The applicant is not proposing to apply glufosinate to the GM wheat in the field trials except for selection during field breeding.
   * 1. Potential adverse health effects of the GM wheat
4. In 2022, FSANZ approved the use of HB4 wheat as food. The safety assessment ([FSANZ, 2021](#_ENREF_10)) considered data regarding:

* potential toxicity or allergenicity of the introduced Hahb-4 protein
* potential toxicity or allergenicity of the introduced PAT protein
* potential toxicity or allergenicity of putative peptides encoded by open reading frames created by the DNA insertions, and
* compositional analysis of whole grain from HB4 wheat.

Based on this information, the FSANZ assessment concluded that no health or safety concerns were identified for HB4 wheat. Food derived from HB4 wheat is considered as safe for human consumption as food derived from non‑GM wheat.

1. In an animal nutritional study, 120 broiler chickens were fed flour from HB4 wheat as 40% of their diet over a six-week period. The chickens fed HB4 wheat gained weight at the same rate as control chickens fed with the non-GM parental wheat. The study also examined general health of the chickens twice per day, as well as monitoring mortality, and did not report any differences between chickens fed the HB4 wheat or the non-GM parental wheat ([Miranda et al., 2022](#_ENREF_29)).
2. As discussed in Section 3, non-GM wheat contains a number of protein allergens. As the Hahb-4 protein is a transcription factor that affects transcription of many genes (see Section 4.3), it is possible that HB4 wheat could have altered levels of some endogenous wheat allergens. A paper studying the effect of *HaHB4* on defence genes found that constitutive expression of *HaHB4* induces increased expression of trypsin inhibitor enzymes in sunflower, maize and Arabidopsis plants, for example a 6‑fold increase in transcript levels of trypsin inhibitor 2 in transformed sunflower leaves compared to a non-transgenic control ([Manavella et al., 2008](#_ENREF_27)). Several proteins from the wheat α‑amylase/trypsin inhibitor family have been identified as important allergens in baker’s asthma, the allergic response to inhalation of wheat flour ([Salcedo et al., 2011](#_ENREF_37)). Similarly, constitutive expression of *HaHB4* causes a 5-fold increase in transcript levels of serine protease inhibitor 1 in transformed sunflower leaves ([Manavella et al., 2008](#_ENREF_27)), and a serine protease inhibitor is a known wheat allergen ([Salcedo et al., 2011](#_ENREF_37)). It is plausible that HB4 wheat could contain increased levels of wheat allergens from the α-amylase/trypsin inhibitor family and/or the serine protease inhibitor family.
3. The Brazilian risk assessment for HB4 wheat in food or feed analysed data on the differential expression of genes between HB4 wheat grains and wheat grains from the non-GM parental variety. Under normal growing conditions, 258 genes were overexpressed in HB4 wheat grains, and 19 of the overexpressed genes have been previously identified as encoding potentially allergenic proteins. However, the increased levels of expression of these 19 genes were still within the range of expression levels found in other wheat genotypes ([CTNBio, 2021](#_ENREF_6)).
4. No published data was found regarding levels of endogenous wheat allergens in HB4 pollen or vegetative tissue. The *HaHB4* gene is derived from sunflower. In sunflower, water stress strongly induces expression of *HaHB4* in vegetative tissues, but expression is not detectable in reproductive organs ([Gago et al., 2002](#_ENREF_11); [Dezar et al., 2005a](#_ENREF_8)). This suggests that the *HaHB4* gene is evolved to have activity in vegetative tissue rather than reproductive tissue, so is likely to have a greater effect on gene expression levels in vegetative tissue than in reproductive tissue.
5. If HB4 wheat has increased levels of endogenous wheat allergens, people with a wheat allergy could have a stronger reaction to HB4 wheat than to non-GM wheat. In a study of six patients with wheat allergy who had an early asthmatic response to inhalation of non-GM wheat flour proteins, the dose-response curves were not linear, but all patients showed a clear trend of increasing dose of inhaled wheat proteins causing increasing impairment of lung function ([Salvatori et al., 2008](#_ENREF_38)).
6. Gluten, the trigger for autoimmune responses in coeliac disease, accounts for approximately 80% of total protein in wheat grain ([Rej et al., 2020](#_ENREF_36)). A compositional study found that the total protein content of HB4 wheat grain is not significantly different from the non-GM parental wheat ([Ayala et al., 2019](#_ENREF_4)). Therefore, the gluten content in HB4 wheat grain could not be different from the non-GM parental wheat by more than a few percent. This is negligible compared to variations in gluten content between non-GM commercial wheat cultivars, which are reported to contain from 5.8 to 12.7 g gluten per 100 g flour ([Schuster et al., 2022](#_ENREF_39)).
7. The applicant states that HB4 wheat has been extensively field tested in several countries since 2007 and no harmful consequences were observed.
   * 1. Characterisation of the GMOs
8. Field trials of HB4 wheat were conducted at 37 field trial sites in Argentina between 2009 and 2017. HB4 wheat had higher average grain yield than the non-GM parental wheat: 16% higher at trial sites with water deficit conditions and 3% higher at trial sites with no water deficit. The difference in grain yield was due to increased grain number per square metre rather than increased grain size. Average water use efficiency of HB4 wheat was calculated as 9% higher than the non-GM parental wheat ([Gonzalez et al., 2019](#_ENREF_13)).
9. HB4 wheat plants grown in a greenhouse had no significant difference in development times or plant height compared to non-GM parental wheat plants. Anthesis and maturity dates of HB4 wheat were measured at one field trial site, and were not significantly different from non-GM parental wheat ([Gonzalez et al., 2019](#_ENREF_13)).
10. The applicant states that HB4 wheat has been extensively field tested in several countries. No unintended phenotypic changes were observed in these field trials.
11. A compositional analysis of field-grown HB4 wheat tested grain samples for 43 nutrients and anti-nutrients and forage samples for 10 nutrients. Results indicated that HB4 wheat is compositionally equivalent to non-GM wheat ([Ayala et al., 2019](#_ENREF_4)).
    1. The receiving environment
12. The receiving environment forms part of the context in which the risks associated with dealings involving the GMOs are assessed. Relevant information about the receiving environment includes abiotic and biotic interactions of the crop with the environment where the release would occur; agronomic practices for the crop; presence of plants that are sexually compatible with the GMO; and background presence of the gene(s) used in the genetic modification ([OGTR, 2013](#_ENREF_32)).
13. Detailed information about non-GM wheat in the Australian environment is presented in the document *The Biology of* Triticum aestivum *L. (Bread Wheat)* ([OGTR, 2021](#_ENREF_33)).
    * 1. Relevant abiotic factors
14. The proposed trial sites may be located in any of 135 LGAs in wheat-growing areas of NSW, Victoria, WA and SA. These LGAs have a range of climate types.
15. The key abiotic stresses affecting wheat crops in Australia are drought stress, heat stress and frost ([GRDC, 2016a](#_ENREF_14), [b](#_ENREF_15)).
    * 1. Relevant biotic factors
16. In Australian agriculture, a range of invertebrate pests including mites, insects and nematodes feed on wheat plants in the field. Birds, kangaroos, rabbits and mice may also feed on wheat crops ([OGTR, 2021](#_ENREF_33)).
17. Most of the important pathogens affecting wheat crops are fungal diseases. Some major fungal diseases are transmitted via a ‘green bridge’ of volunteer cereal plants that survive between growing seasons ([GRDC, 2016b](#_ENREF_15)).
    * 1. Relevant agricultural practices
18. The controls proposed for the field trial are outlined in Section 2.2 of this Chapter. Aside from implementing these controls, it is proposed that the GM wheat would be cultivated using conventional crop management practices for wheat.
19. The GM wheat would be grown as a dryland crop, but drip or pipe irrigation may be used to maintain the crop in challenging weather situations or to control the water regime where necessary. Herbicides and pesticides would be applied according to label instructions to manage the health of the crop. Some GM wheat plants may be tented or bagged to facilitate controlled in-field breeding. The GM wheat would be hand harvested for small areas or harvested with commercial equipment for larger areas.
    * 1. Presence of related plants in the receiving environment
20. Bread wheat (*T. aestivum*) is sexually compatible with other bread wheat or durum wheat (*T. turgidum* subsp. *durum*) plants. Bread wheat is commercially cultivated in all of the LGAs where proposed field trial sites may be located, and durum wheat is cultivated in some of these LGAs. Wheat plants would be present as volunteers as well as crops ([OGTR, 2021](#_ENREF_33)).
21. Triticale, which is a hybrid between wheat and rye, is a minor crop in Australia ([Australian grain production](https://www.aegic.org.au/australian-grain-production-a-snapshot/), accessed 13 May 2024). There is little evidence available regarding whether triticale can naturally cross with bread wheat in the field. However, a greenhouse study using hand pollination found that about 20% of pollination events between bread wheat and triticale where triticale was the female parent produced viable and self-fertile hybrids ([Hills et al., 2007](#_ENREF_19)). Therefore, it is possible that GM wheat could cross-pollinate triticale plants.
22. Rye (*Secale cereale*) is also a minor crop in Australia ([Australian grain production](https://www.aegic.org.au/australian-grain-production-a-snapshot/), accessed 13 May 2024). Very rare natural hybridisation events between bread wheat and rye have been reported in the literature ([Hegde and Waines, 2004](#_ENREF_18)). However, bread wheat and rye are only crossable where bread wheat is the female parent ([Laugerotte et al., 2022](#_ENREF_24)). Therefore, it is not possible for GM wheat to cross-pollinate rye plants.
23. No other plant species that naturally cross with bread wheat and produce fertile offspring are present in the Australian environment. Further details are available in the biology document for wheat ([OGTR, 2021](#_ENREF_33)).
    * 1. Presence of similar genes and encoded proteins in the environment
24. The introduced *HaHB4* gene was derived from sunflower. Sunflower is a minor crop grown in Australia for oil production, bird seed and direct human consumption ([GRDC, 2017](#_ENREF_16)).
25. The introduced *bar* gene was derived from *S. hygroscopicus*, a soil bacterium that was first isolated from Australian soil samples ([Jensen, 1931](#_ENREF_20)). The *bar* gene is also present in several commercial GM crops grown in Australia.
26. People and animals are routinely exposed to these genes and their encoded proteins in the environment.
    1. Relevant Australian and international approvals
       1. Australian approvals
27. In 2022, FSANZ approved use of food derived from HB4 wheat ([application A1232](https://www.foodstandards.gov.au/food-standards-code/applications/A1232-Food-derived-from-drought-tolerant-and-herbicide-tolerant-wheat-line-IND-00412-7)).
28. The Regulator has not previously assessed or approved HB4 wheat.
29. The Regulator has previously approved 24 field trial licences for genetically modified wheat, of which 13 licences are for wheat genetically modified for abiotic stress tolerance. Information on these GM wheat licences is available from the [OGTR GMO Record](https://www.ogtr.gov.au/what-weve-approved/dealings-involving-intentional-release). There have been no reports of adverse effects on human health or the environment resulting from any of these releases.
30. The Regulator has not approved commercial release of any GM wheat in Australia.
    * 1. International approvals
31. HB4 wheat was approved for commercial cultivation in Argentina in 2020, in Brazil in 2023, and in Paraguay in 2023 ([ISAAA website](https://www.isaaa.org/gmapprovaldatabase/event/default.asp?EventID=574); accessed 21 March 2024; [BioTrack Product database](https://biotrackproductdatabase.oecd.org/Product.aspx?id=IND-%C3%98%C3%98412-7); accessed 21 March 2024).
32. In Argentina, commercial HB4 wheat was grown on 53,000 ha in 2021-22 and 44,000 ha in 2022‑23 ([AgbioInvestor, 2024](#_ENREF_3))([USDA Foreign Agricultural Service website](https://fas.usda.gov/regions/argentina); accessed 21 March 2024).
33. HB4 wheat has been approved for food and feed use in Argentina, Brazil, Colombia, Indonesia, Nigeria, Paraguay, South Africa and the United States ([ISAAA website](https://www.isaaa.org/gmapprovaldatabase/event/default.asp?EventID=574); accessed 21 May 2024; [USDA Foreign Agricultural Service website](https://fas.usda.gov/regions/argentina); accessed 21 May 2024).
34. HB4 soybean, which is a GM soybean containing the same introduced genes as HB4 wheat, has been approved for commercial cultivation in Argentina, Brazil, Paraguay, the United States and Canada ([ISAAA website](https://www.isaaa.org/gmapprovaldatabase/event/default.asp?EventID=403); accessed 21 March 2024; [BioTrack Product database](https://biotrackproductdatabase.oecd.org/Product.aspx?id=IND-%C3%98%C3%9841%C3%98-5); accessed 21 March 2024).
35. Risk assessment
    1. Introduction
36. The risk assessment identifies and characterises risks to the health and safety of people or to the environment from dealings with GMOs, posed by or as the result of gene technology (Figure 4). Risks are identified within the established risk assessment context (Chapter 1), taking into account current scientific and technical knowledge. A consideration of uncertainty, in particular knowledge gaps, occurs throughout the risk assessment process.



Figure 4. The risk assessment process

1. The Regulator uses a number of techniques to identify risks, including checklists, brainstorming, previous agency experience, reported international experience and consultation ([OGTR, 2013](#_ENREF_32)).
2. Risk identification first considers a wide range of circumstances in which the GMO, or the introduced genetic material, could come into contact with people or the environment. This leads to postulating causal pathways that may give rise to harm for people or the environment from dealings with a GMO. These are called risk scenarios.
3. Risk scenarios are screened to identify substantive risks, which are risk scenarios that are considered to have some reasonable chance of causing harm. Risk scenarios that could not plausibly occur, or do not lead to harm in the short and long term, do not advance in the risk assessment process (Figure 4), i.e. the risk is considered to be no greater than negligible.
4. Risk scenarios identified as substantive risks are further characterised in terms of the potential seriousness of harm (consequence assessment) and the likelihood of harm (likelihood assessment). The consequence and likelihood assessments are combined to estimate the level of risk and determine whether risk treatment measures are required. The potential for interactions between risks is also considered.
5. A weed risk assessment approach is used to identify traits that may contribute to risks from GM plants, as this approach addresses the full range of potential adverse outcomes associated with plants. In particular, novel traits that may increase the potential of the GMO to spread and persist in the environment or increase the level of potential harm compared with the parental plant(s) are considered in postulating risk scenarios ([Keese et al., 2014](#_ENREF_23)). Risk scenarios postulated in previous RARMPs prepared for licence applications for the same or similar GMOs are also considered.
   1. Risk identification
6. Postulated risk scenarios are comprised of three components (Figure 5):
7. the source of potential harm (risk source)
8. a plausible causal linkage to potential harm (causal pathway)
9. potential harm to people or the environment.




Figure 5. Components of a risk scenario

1. When postulating relevant risk scenarios, the risk context is taken into account, including the following factors detailed in Chapter 1:

* the proposed dealings,
* the proposed limits including the extent and scale of the proposed dealings,
* the proposed controls to limit the spread and persistence of the GMO, and
* the characteristics of the parent organism(s).
  + 1. Risk source

1. The sources of potential harms can be intended novel GM traits associated with one or more introduced genetic elements, or unintended effects/traits arising from the use of gene technology.
2. As discussed in Chapter 1, Section 4, the GM wheat has been modified by introduction of the *HaHB4* gene conferring environmental stress tolerance. This introduced gene will be considered further as a source of potential harm.
3. The GM wheat also contains the introduced *bar* gene that confers glufosinate herbicide tolerance and is used as a selectable marker gene. The *bar* gene has been previously assessed as a herbicide tolerance gene in RARMPs for multiple commercial GM crops (most recently DIR 190), and as a marker gene in RARMPs for multiple GM wheat field trials (most recently DIR 201). These RARMPs are available from the [OGTR GMO Record](https://www.ogtr.gov.au/what-weve-approved/dealings-involving-intentional-release). As the *bar* gene has not been found to pose a substantive risk to either people or the environment in previous assessments, this introduced gene will not be further considered as a source of potential harm.
4. The GM wheat contains gene sequences derived from the marker genes *bla* and *gus*. As discussed in Chapter 1, Section 4.2, these genes are not expected to be expressed as proteins, so would have no effect on the phenotype of the GM wheat. People or other organisms could only be exposed to the DNA sequences, and dietary DNA has no toxicity ([Delaney et al., 2018](#_ENREF_7)). Therefore, these gene sequences will not be further considered as a source of potential harm.
5. The introduced genes are controlled by introduced regulatory sequences. Regulatory sequences, such as promoters, enhancer sequences and terminators, are naturally present in all plants and the introduced sequences are expected to operate in similar ways to endogenous sequences. The regulatory sequences are DNA that is not expressed as a protein, so exposure is to the DNA only and dietary DNA has no toxicity ([Delaney et al., 2018](#_ENREF_7)). Hence, potential for harm from the regulatory elements will not be considered further.
   * 1. Causal pathway
6. The following factors are considered when postulating plausible causal pathways to potential harm:

* routes of exposure to the GMOs, the introduced gene(s) and gene product(s)
* potential exposure to the introduced gene(s) and gene product(s) from other sources in the environment
* the environment at the site(s) of release
* agronomic management practices for the GMOs
* spread and persistence of the GMOs (e.g. reproductive characteristics, dispersal pathways and establishment potential)
* tolerance to abiotic conditions (e.g. climate, soil and rainfall patterns)
* tolerance to biotic stressors (e.g. pests, pathogens and weeds)
* tolerance to cultivation management practices
* gene transfer to sexually compatible organisms
* gene transfer by horizontal gene transfer
* unauthorised activities.

1. Although all of these factors are taken into account, some are not included in the risk scenarios because they have been considered in previous RARMPs and are not expected to give rise to substantive risks.
2. The potential for horizontal gene transfer (HGT) and any possible adverse outcomes has been reviewed in the literature ([Keese, 2008](#_ENREF_22); [Philips et al., 2022](#_ENREF_34)) and assessed in previous RARMPs. No risk greater than negligible was identified, due to the rarity of HGT events and because the gene sequences are already present in the environment and available for transfer via demonstrated natural mechanisms. Therefore, HGT will not be assessed further.
3. Previous RARMPs have considered the potential for unauthorised activities to lead to an adverse outcome. The Act provides for substantial penalties for non-compliance and unauthorised dealings with GMOs. The Act also requires the Regulator to have regard to the suitability of the applicant to hold a licence prior to the issuing of a licence. These legislative provisions are considered sufficient to minimise risks from unauthorised activities, and no risk greater than negligible was identified in previous RARMPs. Therefore, unauthorised activities will not be considered further.
   * 1. Potential harm
4. Potential harms from GM plants are based on those used to assess the risk from weeds ([Virtue, 2008](#_ENREF_44); [Keese et al., 2014](#_ENREF_23)) including:

* harm to the health of people or desirable organisms, including toxicity/allergenicity
* reduced biodiversity for nature conservation
* reduced establishment or yield of desirable plants
* reduced products or services from the land use
* restricted movement of people, animals, vehicles, machinery and/or water
* reduced quality of the biotic environment (e.g. providing food or shelter for pests or pathogens) or abiotic environment (e.g. negative effects on fire regimes, nutrient levels, soil salinity, soil stability or soil water table).

1. Judgements of what is considered harm depend on the management objectives of the land where the GM plant may be present. For example, a plant species may have a different weed risk potential in different land uses such as dryland cropping or nature conservation.
   * 1. Postulated risk scenarios
2. Three risk scenarios were postulated and screened to identify any substantive risks. These scenarios are summarised in Table 5 and examined in detail in Sections 2.5 - 2.7 (this Chapter).
3. In the context of the activities proposed by the applicant and considering both the short and long term, none of the three risk scenarios gave rise to any substantive risks.

Table 5. Summary of risk scenarios from the proposed dealings

| **Risk scenario** | **Risk source** | **Causal pathway** | **Potential harm** | **Substantive risk?** | **Reason** |
| --- | --- | --- | --- | --- | --- |
| 1 | Introduced *HaHB4* gene | GM wheat grows at the field trial sites  🡇  GM wheat expresses *HaHB4* transcription factor and altered levels of endogenous wheat genes  🡇  Exposure of people who deal with the GM plants, or people in the vicinity of the trial sites, or animals that eat GM plant material | Increased toxicity or allergenicity to people  OR  Increased toxicity to desirable animals | No | * GM plant material would not be used as human food or livestock feed * The small size and short duration of the proposed trial would restrict consumption of GM plant material by wild animals * Proposed limits and controls would minimise exposure of people who may be sensitive to GM plant material * FSANZ has assessed food containing HB4 wheat as safe for human consumption |
| 2 | Introduced *HaHB4* gene conferring environmental stress tolerance | GM wheat grows at the field trial sites  🡇  Pollen flow from the GM wheat to non‑GM plants outside the trial sites  🡇  Establishment of populations of GM wheat expressing *HaHB4* in the environment | Increased toxicity or allergenicity to people  OR  Increased toxicity to desirable animals  OR  Reduced establishment or yield of desirable plants  OR  Increased reservoir for pathogens or pests | No | * Wheat has low levels of outcrossing * The proposed controls would minimise pollen flow from the GM wheat to non-GM plants outside the trial sites * GM wheat volunteers could be controlled by most standard weed management measures * FSANZ has assessed food containing HB4 wheat as safe for human consumption |
| 3 | Introduced *HaHB4* gene conferring environmental stress tolerance | GM wheat grows at the field trial sites  🡇  Persistence of GM wheat seed at the trial sites or dispersal of GM seed outside the trial sites  🡇  Establishment of populations of GM wheat expressing *HaHB4* in the environment | Increased toxicity or allergenicity to people  OR  Increased toxicity to desirable animals  OR  Reduced establishment or yield of desirable plants  OR  Increased reservoir for pathogens or pests | No | * The proposed controls would minimise persistence of GM wheat at the trial sites * The proposed controls would minimise dispersal of GM wheat outside trial sites * GM wheat volunteers could be controlled by most standard weed management measures * FSANZ has assessed food containing HB4 wheat as safe for human consumption |

* + 1. Risk scenario 1

| *Risk Source* | Introduced *HaHB4* gene |
| --- | --- |
| *Causal Pathway* | GM wheat grows at the field trial sites  🡇  GM wheat expresses *HaHB4* transcription factor and altered levels of endogenous wheat genes  🡇  Exposure of people who deal with the GM plants, or people in the vicinity of the trial sites, or animals that eat GM plant material |
| *Potential Harm* | Increased toxicity or allergenicity to people  OR  Increased toxicity to desirable animals |

**Risk source**

1. The source of potential harm for this postulated risk scenario is the introduced *HaHB4* gene in the GM wheat.

**Causal Pathway**

1. HB4 wheat would be grown at the field trial sites. The introduced *HaHB4* gene is under the control of a constitutive promoter, so the encoded Hahb-4 protein is likely to be produced in all GM wheat plant tissues. As Hahb-4 is a transcription factor that affects the transcription of many genes (Chapter 1, Section 4.3), any plant tissues containing Hahb-4 are also expected to have altered levels of endogenous wheat proteins.
2. The applicant proposes that HB4 wheat grown in the trial would not be used as human food. Therefore, people would not be exposed to the GM plant material through food.
3. People conducting the dealings could be exposed to GM plant material via inhalation of pollen during flowering, inhalation of wheat dust during harvesting operations, inhalation of flour during milling or experimentation, or skin contact with plant tissues. Due to the small scale of the proposed trial, only a limited number of people would engage in dealings with the GM plant material.
4. Wheat pollen is wind dispersed, and although most pollen falls within 3 m of the source plant, some travels up to 60 m ([reviewed in Hegde and Waines, 2004](#_ENREF_18)). Therefore, people who are not involved with the trial but who pass within 60 m of a planting area while the GM wheat is flowering could be exposed to low levels of GM pollen via inhalation. However, due to the small scale of the proposed trial and the location of field trial sites in agricultural areas, only a very limited number of people not involved with the trial could be exposed to small amounts of GM pollen.
5. The applicant proposes that HB4 wheat grown in the trial would not be used as animal feed. Therefore, livestock would not be exposed to the GM plant material.
6. Desirable wild animals, including birds and insects, could enter the trial sites and eat GM plant material. However, the small size and short duration of the proposed field trial would restrict the number of animals that could be exposed to the GM wheat.

**Potential harm**

1. FSANZ has approved use of food derived from HB4 wheat, which is considered as safe for human consumption as food derived from non-GM wheat. The safety assessment ([FSANZ, 2021](#_ENREF_10)) considered data characterising the introduced Hahb-4 protein and concluded that the Hahb-4 protein is unlikely to be directly toxic or allergenic. A number of other countries have also approved the use of HB4 wheat as food and feed (see Chapter 1, Section 6.2).
2. As Hahb-4 is a transcription factor, the GM wheat is expected to have altered levels of endogenous wheat proteins. Non-GM wheat is not known to produce protein toxins ([OGTR, 2021](#_ENREF_33)), so altered levels of endogenous proteins in the GM wheat would not cause increased toxicity. However, as discussed in Chapter 1, Section 4.4, non-GM wheat does produce a number of protein allergens, and a study reports that HB4 wheat grain has increased levels of expression of genes encoding 19 potential endogenous allergens compared to the non-GM parental cultivar, although the increased expression was within the reported range for other non-GM wheat cultivars. There is uncertainty regarding whether these increases have biological significance, especially in plant tissues other than grain. If HB4 wheat produces biologically significant increased levels of one or more wheat allergens, people who are sensitive to these wheat allergens could have a stronger reaction to HB4 wheat than to non-GM wheat. The applicant proposes to not engage persons who have a known sensitivity to wheat to conduct dealings with the GM wheat, and this measure would reduce any risks from increased levels of wheat allergens.
3. As discussed in Chapter 1, Section 4.4, the gluten content of the GM wheat is not meaningfully different from non-GM wheat. Therefore, the genetic modifications are not expected to cause harm to people with coeliac disease.
4. A study of GM Arabidopsis and maize plants that constitutively express *HaHB4* demonstrated upregulation of herbivory defence genes, including genes encoding anti-nutrients such as protease inhibitors ([Manavella et al., 2008](#_ENREF_27)). Therefore, HB4 wheat could have increased levels of anti-nutrients compared to non-GM wheat, which would reduce the nutritional value of the GM plant material. However, a feeding study where chickens were fed flour from HB4 wheat found that HB4 wheat grains had the same nutritional value as non-GM wheat grains ([Miranda et al., 2022](#_ENREF_29)). Although other tissues of HB4 wheat could still have lower nutritional value than non-GM wheat tissue, this is unlikely to harm desirable wild animals or birds that feed on the GM wheat at trial sites, as there are other food sources in the vicinity of trial sites.
5. As discussed in Chapter 1, Section 4.4, there have been extensive field trials of HB4 wheat outside Australia and no harmful consequences were observed.

**Conclusion**

1. Risk scenario 1 is not identified as a substantive risk because GM plant material would not be used as human food or livestock feed, the small size and short duration of the proposed trial would restrict consumption of GM plant material by wild animals, and proposed limits and controls would minimise exposure of people who may be sensitive to GM plant material. In addition, FSANZ has assessed food containing HB4 wheat as safe. Therefore, this risk could not be greater than negligible and does not warrant further detailed assessment.
   * 1. Risk scenario 2

| *Risk Source* | Introduced *HaHB4* gene conferring environmental stress tolerance |
| --- | --- |
| *Causal Pathway* | GM wheat grows at the field trial sites  🡇  Pollen flow from the GM wheat to non‑GM plants outside the trial sites  🡇  Establishment of populations of GM wheat expressing *HaHB4* in the environment  |
| *Potential Harm* | Increased toxicity or allergenicity to people  OR  Increased toxicity to desirable animals  OR  Reduced establishment or yield of desirable plants  OR  Increased reservoir for pathogens or pests |

**Risk source**

1. The source of potential harm for this postulated risk scenario is the introduced *HaHB4* gene in the GM wheat, which confers the trait of environmental stress tolerance.

**Causal Pathway**

1. HB4 wheat would be grown at the field trial sites. When the GM wheat flowers, GM pollen could be carried by wind to sexually compatible plants growing in the vicinity of the trial sites. If these related plants are also flowering, the GM pollen could fertilise some flowers, producing hybrid GM seed.
2. As discussed in Chapter 1, Section 5.4, bread wheat is sexually compatible with other bread wheat or durum wheat plants, and may be able to cross-pollinate triticale plants. Plants of these species could be present in the vicinity of the trial sites either as cultivated crops or as volunteers.
3. Wheat is largely self-pollinating. A study of gene flow in bread wheat found that the average rate of cross pollination from a pollen donor field to recipient plants adjacent to the field was <0.5%. The rate of cross-pollination declined rapidly with distance, and was <0.01% in recipient plants 60 m or more from the donor field ([Matus-Cádiz et al., 2004](#_ENREF_28)). A second study found that the rate of cross-pollination from a pollen donor field to adjacent recipient plants was <0.5%, and no cross-pollination was detected at distances of 44 m or more ([Hanson et al., 2005](#_ENREF_17)). Cross-pollination rates in bread wheat vary depending on the recipient cultivar. In a study using 18 different commercial wheat cultivars as recipients, cross-pollination rates from a source field to plants at distances ≤6 m from the pollen source averaged 0.34% for all cultivars combined, but for some recipient cultivars the average rate was <0.1% and for one recipient cultivar the average rate was 1.66% ([Gaines et al., 2007](#_ENREF_12)). Interspecific cross-pollination from bread wheat to durum wheat occurs at lower levels than intraspecific cross-pollination between bread wheat plants ([Matus-Cádiz et al., 2004](#_ENREF_28)).
4. The *HaHB4* gene is derived from sunflower. In sunflower, water stress strongly induces expression of *HaHB4* in vegetative tissues, but expression is not detectable in reproductive organs ([Gago et al., 2002](#_ENREF_11); [Dezar et al., 2005a](#_ENREF_8)). This indicates that *HaHB4* has not evolved to have activity in reproductive tissue in its source plant, although it could have incidental activity in reproductive tissue when controlled by a constitutive promoter. The applicant conducted extensive field trials of HB4 wheat, and reported that the genetic modification did not alter any reproductive aspects, including pollen viability, of the HB4 wheat compared to the non-GM parent.
5. The applicant proposes to surround each GM wheat planting area with a monitoring zone, inspection zone and isolation zone, as described in Chapter 1, Section 2.2. GM wheat plants flowering during the field trial would be separated from any sexually compatible non-GM crops by a distance of at least 200 m, and would be separated from any sexually compatible non-GM volunteer plants by a distance of at least 60 m. In addition, GM wheat planting areas would be monitored after harvest and any wheat volunteers would be destroyed before flowering. The suitability of the proposed controls to manage pollen flow is discussed in detail in Chapter 3, Section 3.1.3. These controls are expected to minimise pollen flow from the GM wheat to sexually compatible non-GM plants outside the trial sites.
6. In the unlikely event of pollen flow from the GM wheat to sexually compatible non-GM crops or volunteer plants in the environment despite the proposed controls, the recipient plants would still be predominantly self-pollinated. A small proportion of seeds produced by the non-GM crops or volunteer plants could be hybrid GM seeds that contain the *HaHB4* gene. The hybrid GM seeds could be eaten by people or by desirable animals, or could grow into GM wheat plants in the environment.
7. Wheat is a domesticated plant that does not compete well with other vegetation ([OGTR, 2021](#_ENREF_33)), as reflected by its low weed risk rating (Chapter 1, Section 3). The introduced *HaHB4* gene in GM wheat is expected to confer increased tolerance to drought stress, salt stress and biotic stress from invertebrate feeding, but it would not reverse the traits acquired during wheat domestication, that have contributed to its non-weedy habit. Therefore, even if GM wheat plants entered the environment as volunteers, they would not be expected to spread widely or establish populations with long term persistence.

**Potential harm**

1. If the GM wheat entered the Australian environment, the postulated potential harms are increased toxicity or allergenicity to people, increased toxicity to desirable animals, reduced establishment or yield of desirable plants, or an increased reservoir for pathogens or pests.
2. As discussed in Risk Scenario 1, FSANZ has approved use of HB4 wheat as food, and HB4 wheat is not expected to be toxic to people or animals.
3. As discussed in Risk Scenario 1, it is uncertain whether HB4 wheat has increased levels of any endogenous wheat allergens. However, as discussed in the causal pathway above, GM wheat could only plausibly be a small proportion of any wheat crop or volunteer wheat population in the environment. Even if the GM wheat contained increased levels of endogenous wheat allergens, this would have a negligible effect on total allergen levels in flour milled from a predominantly non-GM wheat crop. Similarly, low-level presence of the GM wheat would have a negligible effect on total allergen levels in airborne pollen produced by a predominantly non-GM wheat crop or volunteer wheat population.
4. The introduced *HaHB4* gene is expected to confer increased tolerance to environmental stresses, especially drought stress (Chapter 1, Section 4.3). Therefore, GM wheat volunteers could have increased short-term persistence in the environment compared to non-GM wheat volunteers. For example, many Australian wheat growing areas have winter-dominated rainfall, and grow wheat as a winter crop. In these agricultural areas, GM wheat volunteers could survive better over the dry summer than non-GM wheat volunteers. GM wheat volunteers that persist between growing seasons could provide a reservoir for wheat pests or pathogens, such as fungal diseases, that could attack subsequent wheat crops (Chapter 1, Section 5.2). Persistent GM wheat volunteers could also become weeds that reduce the establishment or yield of subsequent non-wheat crops.
5. However, farmers typically manage crop plant volunteers in the same way that they manage other weeds. GM wheat volunteers could be controlled by most standard weed management measures, such as cultivation, heavy grazing or the use of appropriate herbicides. GM wheat volunteers are unlikely to be controlled by glufosinate herbicides, due to the introduced *bar* gene conferring glufosinate tolerance. Aside from glufosinate, there are many other herbicides (from at least four different mode of action groups) that are registered for control of volunteer wheat, volunteer cereals, and/or grass weeds during summer fallow ([APVMA website](https://portal.apvma.gov.au/pubcris), accessed 30 April 2024).

**Conclusion**

1. Risk scenario 2 is not identified as a substantive risk because wheat has low levels of outcrossing, the proposed field trial controls would minimise pollen flow from the GM wheat to non‑GM plants outside the trial sites, and any GM wheat volunteers could be controlled by most standard weed management measures. In addition, FSANZ has assessed food containing HB4 wheat as safe. Therefore, this risk could not be considered greater than negligible and does not warrant further detailed assessment.
   * 1. Risk scenario 3

| *Risk Source* | Introduced *HaHB4* gene conferring environmental stress tolerance |
| --- | --- |
| *Causal Pathway* | GM wheat grows at the field trial sites  🡇  Persistence of GM wheat seed at the trial sites or dispersal of GM seed outside the trial sites  🡇  Establishment of populations of GM wheat expressing *HaHB4* in the environment |
| *Potential Harm* | Increased toxicity or allergenicity to people  OR  Increased toxicity to desirable animals  OR  Reduced establishment or yield of desirable plants  OR  Increased reservoir for pathogens or pests |

**Risk source**

1. The source of potential harm for this postulated risk scenario is the introduced *HaHB4* gene in the GM wheat, which confers the trait of environmental stress tolerance.

**Causal Pathway**

1. HB4 wheat would be grown at the field trial sites and would produce seed. If a GM wheat seedbank persisted at the trial sites after completion of the trial, or if GM seed dispersed outside the trial sites, volunteer GM wheat expressing *HaHB4* could grow in the environment.
2. As discussed in Risk Scenario 2, the *HaHB4* gene is derived from sunflower. In sunflower, water stress strongly induces expression of *HaHB4* in vegetative tissues, but expression is not detectable in reproductive organs or seed ([Gago et al., 2002](#_ENREF_11); [Dezar et al., 2005a](#_ENREF_8)). This indicates that *HaHB4* has not evolved to have activity in seed in its source plant, although it could have incidental activity in seed when controlled by a constitutive promoter. Following extensive field trials of HB4 wheat, the applicant reported that there were no unintended changes to phenotype, including seed germination and dormancy characteristics, of HB4 wheat compared to the non-GM parental wheat.

###### Persistence of GM wheat on the trial sites

1. The applicant proposes to clean the trial sites after harvest. This is expected to destroy live GM wheat plants on the trial sites, but would not be expected to destroy all GM wheat seeds. For example, if the trial sites are cleaned by tillage, GM seeds lost during harvest would remain on the trial sites under the soil surface.
2. Wheat has low seed dormancy. A small field trial of wheat persistence in Europe found that 87% of wheat volunteers emerged in the first month post-harvest, 11% in the second month, 1% in the third month, and no volunteer emergence was observed in the following three months ([Kalinina et al., 2015](#_ENREF_21)). A large field trial over nine years in Australia found that emergence of volunteer wheat was greatly reduced by two months after harvest, but viable wheat seed could persist for at least six months post-harvest during dry seasons in no-tillage plots ([Wicks et al., 2000](#_ENREF_46)). In previous Australian field trials of GM wheat licensed by the Regulator, most wheat volunteers emerged within a few months after harvest, but sometimes small numbers of wheat volunteers emerged under favourable germination conditions up to 20 months after harvest.
3. The applicant proposes post-harvest monitoring of each trial site for two years with tillage and irrigation. Any wheat volunteers found would be destroyed prior to flowering. The suitability of the proposed controls to manage persistence of GMOs is further discussed in Chapter 3, Section 3.1.4. These control measures are expected to minimise persistence of viable GM wheat seeds on the trial sites.

###### Dispersal of GM wheat outside the trial sites

1. Dispersal of GM wheat seeds outside the trial sites could potentially occur through the activity of people or animals or through transport by wind or water.
2. Human activity is the most important dispersal pathway for non-GM wheat seed ([OGTR, 2021](#_ENREF_33)). Important mechanisms for inadvertent seed dispersal by people include dispersal via equipment such as harvesters, and grain loss during transport. The applicant has proposed controls for the field trial including only permitting authorised persons to access the trial sites, inspecting and cleaning all equipment used on trial sites prior to use for any other purpose, and transporting and storing GMOs in accordance with the current Regulator's [Guidelines for the Transport, Storage and Disposal of GMOs](https://www.ogtr.gov.au/resources/publications/guidelines-transport-storage-and-disposal-gmos). In addition, the GM wheat would not be used as human food, so there would be no opportunity for grain dispersal during transport or processing for food use. These control measures would minimise dispersal of GM wheat seed outside the trial sites by human activity.
3. Dispersal of non-GM wheat seed by animals is discussed in *The Biology of* Triticum aestivum *L. (Bread Wheat)* ([OGTR, 2021](#_ENREF_33)). Pathways known to contribute to dispersal of wheat seed are consumption and excretion of whole seeds by cattle and sheep, transport of seeds in the wool of sheep, transport of seeds by rodents for hoarding, or consumption and excretion of whole seeds by birds.
4. The applicant proposes that the GM wheat will not be used as animal feed. Therefore, cattle and sheep would not be permitted to enter the trial sites, and would not disperse GM wheat seed. The applicant proposes to control rodents on trial sites. In addition, planting areas would be surrounded by a 10 m monitoring zone kept free of vegetation or mown, which would deter rodents from transporting seeds through the area. The applicant does not propose specific controls to restrict dispersal of GM wheat by birds. However, <0.3% of wheat seeds consumed by birds are reported to remain viable after excretion ([Woodgate et al., 2011](#_ENREF_47)), and only a small proportion of any excreted seed would be deposited in places conducive to germination. The potential for dispersal of GM wheat seeds by animals or birds would be further reduced by the small scale of the proposed field trial, and by cleaning the field trial sites after harvest. Therefore, the proposed control measures would minimise dispersal of GM wheat seed outside the trial sites by animal activity.
5. Wheat seeds are not usually dispersed by wind as wheat has non-shattering seed heads, seeds are heavy and they lack specialised structures to aid windborne dispersal ([OGTR, 2021](#_ENREF_33)). It is possible that GM wheat seeds could be dispersed by high winds if a severe storm occurred while mature seed was present on plants or the soil surface. Wheat seeds on the soil surface could also be transported by water during heavy runoff or flooding. The applicant has proposed that all field trial sites would be located at least 50 m from any natural waterway, which would minimise the potential for seed dispersal through flooding.

**Potential harm**

1. If the GM wheat entered the Australian environment, the postulated potential harms are increased toxicity or allergenicity to people, increased toxicity to desirable animals, reduced establishment or yield of desirable plants, or an increased reservoir for pathogens or pests. These potential harms are all discussed in Risk Scenario 2.
2. As discussed in Risk Scenario 1, FSANZ has approved use of HB4 wheat as food, and HB4 wheat is not expected to be toxic to people or animals.
3. As discussed in Risk Scenario 2, GM wheat volunteers could be controlled by most standard weed management measures.

**Conclusion**

1. Risk scenario 3 is not identified as a substantive risk because the proposed field trial controls would minimise persistence of GM wheat at the trial sites and dispersal of GM wheat outside trial sites. In addition, GM wheat volunteers could be controlled by most standard weed management measures and FSANZ has assessed food containing HB4 wheat as safe. Therefore, this risk could not be considered greater than negligible and does not warrant further detailed assessment.
   1. Uncertainty
2. Uncertainty is an intrinsic part of risk and is present in all aspects of risk analysis. This is discussed in detail in the Regulator’s [Risk Analysis Framework](https://www.ogtr.gov.au/resources/publications/risk-analysis-framework-2013) document.
3. Uncertainty is addressed by approaches such as balance of evidence, conservative assumptions, and applying risk management measures that reduce the potential for risk scenarios involving uncertainty to lead to harm. If there is residual uncertainty that is important to estimating the level of risk, the Regulator will take this uncertainty into account in making decisions.
4. As field trials of GMOs are designed to gather data, there are generally data gaps when assessing the risks of a field trial application. However, field trial applications are required to be limited and controlled. Even if there is uncertainty about the characteristics of a GMO, limits and controls restrict exposure to the GMO, and thus decrease the likelihood of harm.
5. For DIR 204, uncertainty is noted particularly in relation to potential for increased levels of endogenous wheat allergens in the GM wheat, especially in plant tissues other than the grain.
6. Additional data, including information to address this uncertainty, may be required to assess possible future applications with reduced limits and controls, such as a larger scale trial or the commercial release of these GMOs.
7. Chapter 3, Section 4, discusses information that may be required for future release.
   1. Risk evaluation
8. Risk is evaluated against the objective of protecting the health and safety of people and the environment to determine the level of concern and, subsequently, the need for controls to mitigate or reduce risk. Risk evaluation may also aid consideration of whether the proposed dealings should be authorised, need further assessment, or require collection of additional information.
9. Factors used to determine which risks need treatment may include:

* risk criteria
* level of risk
* uncertainty associated with risk characterisation
* interactions between substantive risks.

1. Three risk scenarios were postulated whereby the proposed dealings might give rise to harm to people or the environment. In the context of the limits and controls proposed by the applicant, and considering both the short and long term, none of these scenarios were identified as substantive risks. The principal reasons for these conclusions are summarised in Table 5 and include:

* GM plant material would not be used as human food or animal feed
* limits on the size and duration of the proposed release
* suitability of controls proposed by the applicant to restrict the spread and persistence of the GM wheat plants and their genetic material
* wheat has low levels of outcrossing
* GM wheat volunteers could be controlled by most standard weed management measures
* FSANZ has assessed food containing HB4 wheat as safe.

1. Therefore, risks to the health and safety of people, or the environment, from the proposed release of the GM wheat into the environment are considered to be negligible. The *Risk Analysis Framework* ([OGTR, 2013](#_ENREF_32)), which guides the risk assessment and risk management process, defines negligible risks as risks of no discernible concern with no present need to invoke actions for mitigation. Therefore, no additional controls are required to treat these negligible risks. Hence, the Regulator considers that the dealings involved in this proposed release do not pose a significant risk to either people or the environment.
2. Risk management plan
   1. Background
3. Risk management is used to protect the health and safety of people and to protect the environment by controlling or mitigating risk. The risk management plan addresses risks evaluated as requiring treatment and considers limits and controls proposed by the applicant, as well as general risk management measures. The risk management plan informs the Regulator’s decision-making process and is given effect through licence conditions.
4. Under Section 56 of the Act, the Regulator must not issue a licence unless satisfied that any risks posed by the dealings proposed to be authorised by the licence are able to be managed in a way that protects the health and safety of people and the environment.
5. All licences are subject to 3 conditions prescribed in the Act. Section 63 of the Act requires that each licence holder inform relevant people of their obligations under the licence. The other statutory conditions allow the Regulator to maintain oversight of licensed dealings: Section 64 requires the licence holder to provide access to premises to OGTR inspectors and Section 65 requires the licence holder to report any information about risks or unintended effects of the dealing to the Regulator on becoming aware of them. Matters related to the ongoing suitability of the licence holder must also be reported to the Regulator.
6. The licence is also subject to any conditions imposed by the Regulator. Examples of the matters to which conditions may relate are listed in Section 62 of the Act. Licence conditions can be imposed to limit and control the scope of the dealings and to manage risk to people or the environment. In addition, the Regulator has extensive powers to monitor compliance with licence conditions under Section 152 of the Act.
   1. Risk treatment measures for substantive risks
7. The risk assessment of risk scenarios listed in Chapter 2 concluded that there are negligible risks to people and the environment from the proposed field trial of GM wheat. These risk scenarios were considered in the context of the scale of the proposed release (Chapter 1, Section 2.1), the proposed controls (Chapter 1, Section 2.2), and the receiving environment (Chapter 1, Section 5), and considering both the short and the long term. The risk evaluation concluded that no specific risk treatment measures are required to treat these negligible risks. Limits and controls proposed by the applicant and other general risk management measures are discussed below.
   1. General risk management
8. The limits and controls proposed in the application were important in establishing the context for the risk assessment and in reaching the conclusion that the risks posed to people and the environment are negligible. Therefore, to maintain the risk context, licence conditions have been imposed to limit the release to the proposed size, locations and duration, and to restrict the spread and persistence of the GMOs and their genetic material in the environment. The conditions are discussed and summarised in this Chapter and listed in detail in the licence.
   * 1. Limits and controls on the release
9. Sections 2.1 and 2.2 in Chapter 1 list the limits and controls proposed by the applicant. Many of these are discussed in the three risk scenarios considered in Chapter 2. The appropriateness of the limits and controls is considered further in the following sections.
   * + 1. Consideration of limits proposed by the applicant
10. The applicant proposes to conduct the field trial between the date of issue of the licence and December 2029. This would limit the duration of the trial to five years and a few months. The GM wheat would be grown at a maximum of ten trial sites per year, with a planting area of up to 2 ha per site. The small size and short duration of the trial would restrict the exposure of people and desirable animals to the GMOs (Risk scenario 1).
11. The applicant proposes that only authorised persons would enter the trial sites. Standard conditions included in the licence state that only people authorised by the licence holder are covered by the licence and permitted to deal with the GMOs. In addition, the licence holder must inform all people dealing with the GMOs of relevant licence conditions. These measures would ensure that the field trial is conducted in accordance with the specified limits and controls (important for all risk scenarios).
    * + 1. Consideration of proposed controls regarding exposure to the GMOs
12. The applicant proposes not allowing the GMOs or GM products to be used for human food or animal feed. A licence condition states that GM plant material must not be used as food for humans or feed for animals. This condition would restrict the exposure of people and desirable animals to the GMOs (Risk scenario 1) and would also minimise dispersal of the GMOs by livestock or during transport or processing for human food use (Risk scenario 3).
13. The applicant proposes not engaging personnel who have a known allergy to wheat to work with the GM wheat, which could help manage uncertainty about potential allergenicity (Risk scenario 1). If HB4 wheat produces biologically significant increased levels of certain wheat allergens, people who are sensitive to these wheat allergens could have a stronger reaction to HB4 wheat than to comparable non-GM wheat. Due to the small scale of the proposed trial, only a limited number of people would work with the GM wheat, but it is possible that one or more of the potential workers would have a known wheat allergy. A licence condition (above) does not permit the GM wheat to be used as food, so people working with the GM wheat would not be exposed to wheat allergens via consumption. People working with the GM wheat could be exposed to wheat allergens through inhalation or through skin contact. Respiratory wheat allergies are both more frequent and more severe than skin-mediated wheat allergies ([Stobnicka and Gorny, 2015](#_ENREF_40)), which typically only cause mild localised skin symptoms. Therefore, it is considered appropriate to protect people with wheat allergy from inhaling GM wheat material, but unnecessary to protect them from skin contact with GM wheat material. A licence condition states that the licence holder must not permit a person to conduct any dealing which may expose the person to inhalation of GM plant material unless the licence holder has determined that the person does not have a known allergy to wheat. The licence holder could comply with the licence condition either by excluding any workers with a known wheat allergy from dealings at times when there may be airborne GM plant material, or by ensuring that any workers with a known wheat allergy use masks or other protective equipment that prevent them from inhaling airborne GM plant material.
    * + 1. Consideration of proposed controls regarding pollen flow from the GMOs
14. Figure 2 in Chapter 1 shows a schematic diagram of the field trial setup proposed by the applicant. Each GM wheat planting area would be surrounded by a 10 m monitoring zone and a 50 m inspection zone. The monitoring and inspection zones would be inspected while the GMOs are flowering to destroy any wheat or sexually compatible plants. The inspection zone would be surrounded by a 140 m isolation zone where no wheat or sexually compatible plants would be deliberately grown. In two published studies of pollen-mediated gene flow from wheat at field trial scale, involving seven individual trials using 0.25 ha pollen donor plots, average gene flow rates were 0.02% to wheat plants 40 m from the pollen donor plots and 0.004% to wheat plants 100 m from the pollen donor plots ([Matus-Cádiz et al., 2004](#_ENREF_28); [Loureiro et al., 2012](#_ENREF_25)). One hybrid seed was found in 230,000 wheat seeds collected at distances of 180 m to 300 m from the pollen donor plots ([Matus-Cádiz et al., 2004](#_ENREF_28)). Therefore, the combination of a 10 m monitoring zone and a 50 m inspection zone (60 m isolation distance) is expected to minimise pollen flow from the GM wheat to scattered non-GM volunteer plants, and the combination of a 10 m monitoring zone, 50 m inspection zone and 140 m isolation zone (200 m isolation distance) is expected to minimise pollen flow from the GM wheat to non-GM crops outside the trial site (Risk scenario 2). The proposed field trial setup is included in the licence.
15. The applicant did not specify the proposed frequency of inspections of the monitoring and inspection zones to destroy any wheat or sexually compatible plants. The licence requires inspections at least every 14 days from 14 days prior to the expected flowering of the GMOs until 14 days after all GMOs in the planting area have finished flowering.
16. The applicant proposes that more than one planting area could be established at each trial site. Under the conditions in the licence, where more than one planting area is established at a field trial site, all planting areas must be inside a 10 m monitoring zone surrounding the whole trial site (see Figure 1 in licence). Any land between planting areas is also considered part of the monitoring zone.
    * + 1. Consideration of proposed controls regarding persistence of the GMOs
17. After harvest of each trial site, the applicant proposes cleaning of planting areas and destroying all GMOs from the trial not required for testing or future planting. Licence conditions require that trial sites must be cleaned (which would destroy any surviving GM plants) within 14 days after harvest, and that harvested GM seed not required for experimentation or future planting must be destroyed as soon as practicable. In addition, to deal with the case of failed crops that are not harvested, licence conditions require that GMOs must be harvested or destroyed within 8 months after planting, and that if all GMOs in a planting area have been destroyed, the GMOs are considered harvested and the area is considered cleaned.
18. The applicant has only proposed post-harvest cleaning and inspections for planting areas, but these measures would also be needed on some other areas of the trial sites to ensure that all GMOs from the trial are destroyed. A licence condition specifies that the areas requiring post-harvest cleaning and inspections are the planting area, monitoring zone, areas where equipment has been cleaned, and any other areas where GMOs are known to have dispersed. The monitoring zone is considered to require post-harvest cleaning and inspections due to potential seed dispersal during harvest, as the applicant is proposing to use commercial harvesters that must drive into and turn on the monitoring zone. In previous GM wheat trial sites of a similar size to those proposed under DIR 204, and using commercial harvesting equipment, emergence of hundreds or thousands of post-harvest wheat volunteers has been reported in the monitoring zone during post cleaning inspections.
19. The applicant has proposed that GMOs would be destroyed by herbicide application, root cutting and shredding/mulching, uprooting, light tillage to a depth of no more than 5 cm, burning/incineration, autoclaving, seed grinding, milling, or seed burial to a depth of at least 1 m. These methods are considered effective for rendering wheat plants and/or seed non-viable, and have been included in the licence. To ensure the effectiveness of destruction by seed burial, a licence condition specifies how this must be carried out, including a requirement that seeds must be sufficiently irrigated at time of burial to encourage decomposition.
20. The applicant has proposed that non-GM wheat plants grown on the trial sites, such as non-GM wheat varieties grown in the planting area as comparators or for breeding purposes, would be treated as if they are GMOs. Non‑GM wheat in the trial site may be cross-pollinated by the GM wheat, resulting in hybrid seeds. It is therefore appropriate to require non-GM wheat to be destroyed in the same manner as GM wheat, to manage persistence of the GMOs, and this measure is included in the licence.
21. After harvest, the applicant proposes to inspect the trial sites for a period of two years and destroy any volunteer wheat plants found. As discussed in Risk Scenario 3, viable wheat seeds in a seedbank are expected to germinate within two years. To demonstrate that the seedbank is free of GM wheat, a licence condition requires inspections for a period of at least two years and until no wheat volunteers have been detected in the area for at least the final six months of inspections.
22. The proposed frequency of post-harvest inspections is every 55 days. However, the applicant also states that wheat volunteers found during inspections would be destroyed prior to flowering, which would prevent pollen flow to non-GM plants outside the trial site (Risk scenario 2) as well as seed set and persistence (Risk scenario 3). Wheat typically requires 1275 degree-days[[1]](#footnote-1) to grow from emergence to flowering ([Bowden et al., 2008](#_ENREF_5)), which in hot weather (average daily temperature 26°C), would be about 49 days. Considering variations in flowering time between cultivars and between individual plants, trial sites should be inspected at least every 35 days to ensure that wheat volunteers are detected before flowering. This is required by the licence.
23. During the post-harvest monitoring period for each trial site, the applicant proposes one light tillage to a depth of no more than 5 cm and 3 irrigations or equivalent natural rainfall events to promote seedbank germination. An Australian field trial found that wheat seed banks were most persistent during dry seasons in no‑tillage plots ([Wicks et al., 2000](#_ENREF_46)). Shallow tillage after harvest, combined with irrigation, will promote germination, however, deep tillage can encourage prolonged dormancy in seeds ([Ogg and Parker, 2000](#_ENREF_31)). Therefore, the licence requires a shallow post-harvest tillage along with at least 3 post-harvest watering events, at intervals of at least 28 days, with the last required watering event occurring during the final volunteer-free period.
24. The measures described above are expected to minimise the persistence of the GM wheat on the field trial sites (Risk scenario 3).
    * + 1. Consideration of proposed controls to limit dispersal of the GMOs
25. The applicant proposes to inspect and clean all equipment used on trial sites prior to use for any other purpose. The applicant also proposes to transport and store GMOs in accordance with the Regulator's current [Guidelines for the Transport, Storage and Disposal of GMOs](https://www.ogtr.gov.au/resources/publications/guidelines-transport-storage-and-disposal-gmos). These measures would help to minimise dispersal of GMOs outside the trial sites by human activity (Risk Scenario 3) and are included in the licence.
26. The application indicates that the GM wheat may be harvested and threshed either by hand or using commercial equipment. The licence requires that the GM wheat must be harvested and threshed separately from any other crop and that threshing must take place on a planting area or monitoring zone or in a facility approved by the Regulator. These conditions would help to minimise dispersal of GMOs outside the trial sites by human activity.
27. The applicant proposes to control rodents on trial sites. This could be done by use of traps and/or baits in the planting area and surrounding areas. The applicant also proposes maintaining the 10 m monitoring zone either vegetation-free or with vegetation kept mown at a maximum height of 10 cm, to avoid attracting or harbouring rodents. As discussed in Risk Scenario 3, these measures would minimise dispersal of GM wheat seeds by rodents. The licence requires these measures to be taken from planting of GM wheat seeds in a planting area until the planting area is cleaned. Cleaning of a planting area, as defined in the licence, includes removal of most of the GM seeds from the soil surface where they could be readily accessed by rodents or dispersed by other means.
28. The applicant proposes to locate each planting area at least 50 m away from the nearest natural waterway. This measure would restrict the potential for GM wheat seeds to be dispersed by flooding (Risk Scenario 3) and is included in the licence. In addition, licence conditions require that planting areas must not be located in flood-prone areas, and that the licence holder must immediately notify the Regulator of any extreme weather event affecting a trial site, to allow assessment and management of any risks.
    * + 1. Summary of licence conditions to be implemented to limit and control the release
29. A number of licence conditions are imposed to limit and control the release, based on the above considerations. These include requirements to:

* limit the duration of the release to the period between issue of the licence and December 2029
* limit the size of the release to a maximum of 10 sites per year, with each site having a maximum planting area of 2 ha
* not allow the GM plant material to be used for human food or animal feed
* not permit persons with an allergy to wheat to conduct dealings that may expose them to inhalation of GM plant material
* surround each planting area with a 10 m monitoring zone, maintained in a manner that does not attract or harbour rodents, that is inspected while the GMOs are flowering to destroy any wheat or sexually compatible plants
* surround the monitoring zone with a 50 m inspection zone that is inspected while the GMOs are flowering to destroy any wheat or sexually compatible plants
* surround the inspection zone with a 140 m isolation zone where no wheat or sexually compatible plants may be grown
* destroy all harvested GM seed not required for further analysis or future planting
* clean the planting areas after harvest and clean other areas where seed has been dispersed
* apply measures to promote the germination of any wheat seeds that may be present in the soil after harvest, including watering and shallow tillage
* monitor each trial site for at least 24 months after harvest and destroy any wheat plants that may grow, until no volunteers have been detected for a continuous 6 months period
* clean all equipment used on the trial sites
* transport and store the GMOs in accordance with the Regulator’s guidelines
* implement measures to control rodents within the planting areas
* locate trial sites at least 50 m from any natural waterways.
  + 1. Other risk management considerations

1. All DIR licences issued by the Regulator contain a number of conditions that relate to general risk management. These include conditions relating to:

* applicant suitability
* contingency plans
* identification of the persons or classes of persons covered by the licence
* reporting requirements
* access for the purpose of monitoring for compliance.
  + - 1. Applicant suitability

1. In making a decision whether or not to issue a licence, the Regulator must have regard to the suitability of the applicant to hold a licence. Under section 58 of the Act, matters that the Regulator must take into account include:

* any relevant convictions of the applicant
* any revocation or suspension of a relevant licence or permit held by the applicant under a law of the Commonwealth, a State or a foreign country and
* the capacity of the applicant to meet the conditions of the licence.

1. The licence conditions include a requirement for the licence holder to inform the Regulator of any information that would affect their suitability.
2. In addition, the licence holder must have access to an Institutional Biosafety Committee (IBC) and be an accredited organisation under the Act.
   * + 1. Contingency plan
3. The licence holder is required to submit a contingency plan to the Regulator before planting the GMOs. This plan would detail measures to be undertaken in the event of any unintended presence of the GM wheat outside permitted areas.
4. Before planting the GMOs, the licence holder is also required to provide the Regulator with a method to reliably detect the GMOs or the presence of the genetic modifications in a recipient organism.
   * + 1. Identification of the persons or classes of persons covered by the licence
5. The persons covered by the licence are the licence holder and employees, agents or contractors of the licence holder and other persons who are, or have been, engaged or otherwise authorised by the licence holder to undertake any activity in connection with the dealings authorised by the licence. Prior to growing the GMOs, the licence holder is required to provide a list of people and organisations covered by the licence, or the function or position where names are not known at the time.
   * + 1. Reporting requirements
6. The licence requires the licence holder to immediately report any of the following to the Regulator:

* any additional information regarding risks to the health and safety of people or the environment associated with the dealings
* any contraventions of the licence by persons covered by the licence and
* any unintended effects of the field trial.

1. A number of written notices would also be required under the licence regarding dealings with the GMO, to assist the Regulator in designing and implementing a monitoring program for all licensed dealings. The notices include:

* expected and actual dates of planting
* details of areas planted with the GMOs
* expected dates of flowering
* expected and actual dates of harvest and cleaning after harvest and
* details of inspection activities.
  + - 1. Monitoring for compliance

1. The Act stipulates, as a condition of every licence, that a person who is authorised by the licence to deal with a GMO, and who is required to comply with a condition of the licence, must allow inspectors and other persons authorised by the Regulator to enter premises where a dealing is being undertaken for the purpose of monitoring or auditing the dealing. Post-release monitoring continues until the Regulator is satisfied that all the GMOs resulting from the authorised dealings have been removed from the release sites.
2. If monitoring activities identify changes in the risks associated with the authorised dealings, the Regulator may also vary licence conditions, or if necessary, suspend or cancel the licence.
3. In cases of non-compliance with licence conditions, the Regulator may instigate an investigation to determine the nature and extent of non-compliance. The Act provides for criminal sanctions of large fines and/or imprisonment for failing to abide by the legislation, conditions of the licence or directions from the Regulator, especially where significant damage to the health and safety of people or the environment could result.
   1. Issues to be addressed for future releases
4. Additional information has been identified that may be required to assess an application for a commercial release of the GM wheat or to justify a reduction in limits and controls.
5. This includes additional data regarding levels of endogenous wheat allergens in the GM wheat in comparison to non-GM wheat, especially in plant tissues other than the grain.
   1. Conclusions of the RARMP
6. The risk assessment concludes that the proposed limited and controlled release of GM wheat poses negligible risks to the health and safety of people or the environment as a result of gene technology. These negligible risks do not require specific risk treatment measures.
7. However, licence conditions have been imposed to limit the release to the proposed size, locations and duration, and to restrict the spread and persistence of the GMOs and their genetic material in the environment, as these were important considerations in establishing the context for assessing the risks.

# References

ABARES (2023). Australian Crop Report: December 2023. (Canberra, Australia: Australian Bureau of Agricultural and Resource Economics and Sciences).

AEGIC (2020). Wheat 2030: Anticipated trends in global consumption. (Australian Export Grains Innovation Centre).

AgbioInvestor (2024). Global GM crop area review.

Ayala, F., Fedrigo, G.V., Burachik, M., and Miranda, P.V. (2019). Compositional equivalence of event IND-OO412-7 to non-transgenic wheat. Transgenic Res *28*, 165-176.

Bowden, P., Edwards, J., Ferguson, N., McNee, T., Manning, B., Roberts, K., Schipp, A.*, et al.* (2008). Wheat growth and development. (NSW DPI).

CTNBio (2021). Parecer Técnico: 7795/2021. (Brazil: Comissão Técnica Nacional de Biossegurança).

Delaney, B., Goodman, R.E., and Ladics, G.S. (2018). Food and feed safety of genetically engineered food crops. Toxicological Sciences *162*, 361-371.

Dezar, C.A., Fedrigo, G.V., and Chan, R.L. (2005a). The promoter of the sunflower HD-Zip protein gene *Hahb4* directs tissue-specific expression and is inducible by water stress, high salt concentrations and ABA. Plant Science *169*, 447-456.

Dezar, C.A., Gago, G.M., Gonzalez, D.H., and Chan, R.L. (2005b). *Hahb-4*, a sunflower homeobox-leucine zipper gene, is a developmental regulator and confers drought tolerance to *Arabidopsis thaliana* plants. Transgenic Research *14*, 429-440.

FSANZ (2021). Safety assessment - Application A1232. (Food Standards Australia New Zealand).

Gago, G.M., Almoguera, C., Jordano, J., Gonzalez, D.H., and Chan, R.L. (2002). *Hahb‐4*, a homeobox‐leucine zipper gene potentially involved in abscisic acid‐dependent responses to water stress in sunflower. Plant, Cell & Environment *25*, 633-640.

Gaines, T.A., Byrne, P.F., Westra, P., Nissen, S.J., Henry, W.B., Shaner, D.L., and Chapman, P.L. (2007). An empirically derived model of field-scale gene flow in winter wheat. Crop Science *47*, 2308-2316.

Gonzalez, F.G., Capella, M., Ribichich, K.F., Curin, F., Giacomelli, J.I., Ayala, F., Watson, G.*, et al.* (2019). Field-grown transgenic wheat expressing the sunflower gene HaHB4 significantly outyields the wild type. Journal of Experimental Botany *70*, 1669-1681.

GRDC (2016a). Wheat Northern Region. (Grains Research and Development Corporation).

GRDC (2016b). Wheat Southern Region. (Grains Research and Development Corporation).

GRDC (2017). GrowNotes Sunflowers. (Grains Research and Development Corporation).

Hanson, B.D., Mallory-Smith, C.A., Shafii, B., Thill, C.D., and Zemetra, R.S. (2005). Pollen-mediated gene flow from blue aleurone wheat to other wheat cultivars. Crop Science *45*, 1610-1617.

Hegde, S.G., and Waines, J.G. (2004). Hybridization and introgression between bread wheat and wild and weedy relatives in North America. Crop Science *44*, 1145-1155.

Hills, M.J., Hall, L.M., Messenger, D.F., Graf, R.J., Beres, B.L., and Eudes, F. (2007). Evaluation of crossability between triticale (X *Triticosecale* Wittmack) and common wheat, durum wheat and rye. Environmental Biosafety Research *6*, 249-257.

Jensen, H.L. (1931). Contributions to our knowledge of the Actinomycetales. II. The definition and subdivision of the genus Actinomyces, with a preliminary account of Australian soil Actinomycetes. Proceedings of The Linnean Society of New South Wales *56*, 345-370.

Kalinina, O., Zeller, S.L., and Schmid, B. (2015). Persistence of seeds, seedlings and plants, performance of transgenic wheat in weed communities in the field and effects on fallow weed diversity. Perspectives in Plant Ecology, Evolution and Systematics *17*, 421-433.

Keese, P. (2008). Risks from GMOs due to horizontal gene transfer. Environmental Biosafety Research *7*, 123-149.

Keese, P.K., Robold, A.V., Myers, R.C., Weisman, S., and Smith, J. (2014). Applying a weed risk assessment approach to GM crops. Transgenic Research *23*, 957-969.

Laugerotte, J., Baumann, U., and Sourdille, P. (2022). Genetic control of compatibility in crosses between wheat and its wild or cultivated relatives. Plant Biotechnology Journal *20*, 812-832.

Loureiro, I., Escorial, M.C., Gonzalez, A., and Chueca, M.C. (2012). Pollen-mediated gene flow in wheat (*Triticum aestivum* L.) in a semiarid field environment in Spain. Transgenic Research *21*, 1329-1339.

Manavella, P.A., Arce, A.L., Dezar, C.A., Bitton, F., Renou, J.P., Crespi, M., and Chan, R.L. (2006). Cross-talk between ethylene and drought signalling pathways is mediated by the sunflower *Hahb-4* transcription factor. The Plant Journal *48*, 125-137.

Manavella, P.A., Dezar, C.A., Bonaventure, G., Baldwin, I.T., and Chan, R.L. (2008). *HAHB4*, a sunflower HD-Zip protein, integrates signals from the jasmonic acid and ethylene pathways during wounding and biotic stress responses. The Plant Journal *56*, 376-388.

Matus-Cádiz, M.A., Hucl, P., Horak, M.J., and Blomquist, L.K. (2004). Gene flow in wheat at the field scale. Crop Science *44*, 718-727.

Miranda, P.V., Iglesias, B.F., Charriere, M.V., and Burachik, M. (2022). Drought tolerant wheat IND-OO412-7 is nutritionally equivalent to its non-transgenic comparator. GM Crops & Food *13*, 119-125.

OECD (2002). Series on Harmonization of Regulatory Oversight in Biotechnology, No 25. Module II: Phosphinothricin. Report No. ENV/JM/MONO(2002)14. (Organisation for Economic Cooperation and Development).

Ogg, A.G., and Parker, R. (2000). Control of volunteer crop plants. Report No. EB 1523. (Washington State University Cooperative Extension).

OGTR (2013). Risk Analysis Framework 2013, 4th edn (Canberra, Australia: Office of the Gene Technology Regulator).

OGTR (2021). The Biology of *Triticum aestivum* L. (Bread Wheat) Version 3.2. (Canberra, Australia: Office of the Gene Technology Regulator).

Philips, J.G., Martin-Avila, E., and Robold, A.V. (2022). Horizontal gene transfer from genetically modified plants - Regulatory considerations. Frontiers in Bioengineering and Biotechnology *10*.

Quirce, S., Boyano-Martinez, T., and Diaz-Perales, A. (2016). Clinical presentation, allergens, and management of wheat allergy. Expert Review of Clinical Immunology *12*, 563-572.

Rej, A., Aziz, I., and Sanders, D.S. (2020). Coeliac disease and noncoeliac wheat or gluten sensitivity. Journal of Internal Medicine *288*, 537-549.

Salcedo, G., Quirce, S., and Diaz-Perales, A. (2011). Wheat allergens associated with baker's asthma. Journal of Investigational Allergology and Clinical Immunology *21*, 81-92.

Salvatori, N., Reccardini, F., Convento, M., Purinan, A., Colle, R., De Carli, S., Garzoni, M.*, et al.* (2008). Asthma induced by inhalation of flour in adults with food allergy to wheat. Clinical & Experimental Allergy *38*, 1349-1356.

Schuster, C., Huen, J., and Scherf, K.A. (2022). Comprehensive study on gluten composition and baking quality of winter wheat. Cereal Chemistry *100*, 142-155.

Stobnicka, A., and Gorny, R.L. (2015). Exposure to flour dust in the occupational environment. International Journal of Occupational Safety and Ergonomics *21*, 241-249.

Thompson, C.J., Movva, N.R., Tizard, R., Crameri, R., Davies, J., Lauwereys, M., and Botterman, J. (1987). Characterization of the herbicide-resistance gene *bar* from *Streptomyces hygroscopicus*. EMBO Journal *6*, 2519-2523.

Trigall Genetics (2021). Application to FSANZ for the inclusion of wheat event IND-ØØ412-7 with increased tolerance to environment stresses in Standard 1.5.2 Food Produced Using Gene Technology. (Food Standards Australia New Zealand).

Venter, C., Maslin, K., Arshad, S.H., Patil, V., Grundy, J., Glasbey, G., Twiselton, R.*, et al.* (2016). Very low prevalence of IgE mediated wheat allergy and high levels of cross-sensitisation between grass and wheat in a UK birth cohort. Clinical and Translational Allergy *6*, 22.

Virtue, J.G. (2008). SA weed risk management guide. (Adelaide: Government of South Australia: Department of Water, Land and Biodiversity Conservation).

White, M., Cheal, D., Carr, G.W., Adair, R., Blood, K., Muir, A., and Meagher, D. (2022). Advisory list of environmental weeds in Victoria 2022. (Heidelberg, Victoria: Department of Environment, Land, Water and Planning).

Wicks, G.A., Felton, W.L., Murison, R.D., and Martin, R.J. (2000). Changes in fallow weed species in continuous wheat in northern New South Wales 1981-1990. Australian Journal of Experimental Agriculture *40*, 831-842.

Woodgate, J.L., Steadman, K.J., and Buchanan, K.L. (2011). A study of seed viability following consumption by birds. (Unpublis**hed final report submitt**ed to the OGTR).

# Appendix A: Summary of submissions from prescribed experts, agencies and authorities on the consultation RARMP

The Regulator received several submissions from prescribed experts, agencies and authorities[[2]](#footnote-2) on the consultation RARMP. All issues raised in submissions relating to risks to the health and safety of people and the environment were considered in the context of the currently available scientific evidence and were used in finalising the RARMP that formed the basis of the Regulator’s decision to issue the licence. Advice received is summarised below.

| **Submission** | **Summary of issues raised** | **Comment** |
| --- | --- | --- |
| 1 | No comment to make other than understands the need for research and crop varieties suited to changing conditions. | Noted. |
| 2 | * Agrees that the risk assessment identifies all plausible risk scenarios by which the proposed dealings could potentially give rise to risks relating to the health and safety of people or the environment. * Agrees that the measures to limit and control the release are appropriate for the trial. * Agrees with the overall conclusion of the RARMP. | Noted. |
| 3 | No advice or comments on the RARMP for DIR 204. | Noted. |
| 4 | Have the specific sites for the proposed field trial been identified and when will that information be available? | The licence holder has not yet identified the specific sites where the field trial will occur.  Before planting GM plants at any field trial site, the licence holder must send a notification to the Regulator including the exact location of the site. This information will then be published on the OGTR website, on both the [DIR 204](https://www.ogtr.gov.au/gmo-dealings/dealings-involving-intentional-release/dir-204) webpage and the [Crop field trial map](https://www.ogtr.gov.au/what-weve-approved/crop-field-trial-map). |
| 5 | Overall, satisfied that the proposed genetically modified (GM) wheat field trial poses negligible risks to human health and safety and the environment, as long as the licence conditions are met. | Noted. |
| Animals such as birds or insects are not considered at risk for potential increased toxicity of the GM wheat due to the small size and short duration of trials (Risk scenario 1). But if single feeding events are sufficient for negative impacts (as they are for coeliac disease in humans) then even a short trial duration could impact a significant number of animals that might visit for feeding on any given day. | Risk scenario 1 (Chapter 2) notes that the small size and short duration of the proposed field trial would restrict consumption of GM wheat by animals. Risk scenario 1 and Section 4.4 of Chapter 1 also note that the introduced Hahb-4 protein in the GM wheat is not expected to be directly toxic or to increase levels of endogenous toxins, and that the gluten content of the GM wheat is not meaningfully different from non-GM wheat. Due to the combination of these factors, the risk of the GM wheat having increased toxicity to animals is considered negligible. |
|  | Mentioned earlier in the document that kangaroos and rabbits are known to feed on wheat, but these species have not been considered when discussing potential for animal-mediated seed dispersal under Risk scenario 3. This section only considers cattle, sheep, rodents, and birds in terms of seed dispersal through consumption/excretion or physical transport. Has there been any consideration of seed dispersal via consumption/excretion or via physical transport in the fur of rabbits and/or kangaroos, both of which are very abundant in the wheatbelt region of Western Australia? | Risk scenario 3 (Chapter 2) notes that dispersal of non-GM seed by animals is discussed in the OGTR biology document *The Biology of* Triticum aestivum *L. (Bread Wheat).* As this biology document is available on the [OGTR website](https://www.ogtr.gov.au/resources/publications/biology-triticum-aestivum-l-bread-wheat), the discussion has not been replicated in full in the RARMP. The biology document includes information on why kangaroos and rabbits are unlikely to disperse wheat seed. In brief:   * Both kangaroos and rabbits prefer to feed on young green grasses rather than dried-out plants bearing mature seed * Viable wheat seeds have not been found in rabbit dung * Wheat seeds do not possess adaptations for dispersal on the fur of animals. |
| The RARMP has determined that the GM wheat has increased potential to persist in the environment compared to non-GM wheat and that the GM wheat may have increased levels of endogenous wheat allergens. As a result, people with a wheat allergy could have a stronger reaction to the GM wheat compared to its non-GM counterparts. Risks relating to these characteristics could be managed by proposed licence conditions as this is a limited and controlled trial and not a commercial release. | Risk scenario 2 (Chapter 2) has been reworded to clarify that, in comparison to non-GM wheat, the GM wheat has increased potential for short-term persistence in the environment but not for long-term persistence in the environment.  Section 3 of Chapter 3 of the RARMP describes the licence conditions imposed to restrict the spread and persistence of GM wheat in the environment and to restrict the exposure of people with wheat allergy to the GM wheat. |
| 6 | Notes that the licence will prohibit the use of GM plant material in human food or animal feed. Does not have any further comments on the licence application at this stage. | Noted. |
| 7 | Satisfied that there is no risk to the human population and that the risks to health and safety from the proposed dealings are negligible as the proposed limits/controls will minimise exposure. Further noting that introduction of genes which confer drought stress resistance in wheat is a benefit to Australia and that the gene product is already approved by an Australia/New Zealand body. | Noted. |
| Reservations regarding the introduction of the *bar* gene used in the strain selection, which confers resistance to glufosinate herbicide. Noting the wide use of herbicide resistance in genetically engineered crops like cotton, it is an inherent risk the engineered plants can become a weed which is herbicide resistant. Suggests testing herbicide susceptibility to other herbicides to control any potential weediness. | Risk scenario 2 in Chapter 2 of the RARMP discusses weed management for GM wheat volunteers. Aside from glufosinate, there are many herbicides (from at least four different mode-of-action groups) that can be used to control volunteer wheat. Wheat volunteers can also be controlled by non-chemical methods such as mowing or tilling. |
| 8 | Agrees that the proposed release poses negligible risk to human health and safety and the environment. The field trials will evaluate HB4 wheat under Australian growing conditions, gather research and regulatory data under Australian growing conditions and whilst some experiments may involve milling GM wheat, it will not be used as human or animal food. | Noted. |
| Note uncertainty in relation to potential for increased levels of endogenous wheat allergens in the GM wheat, especially in plant tissues other than the grain. Suggest that gathering of data on nutritional assessment and compositional analysis include pro‑active assessment of known wheat allergens. Note that the RARMP specifies that additional data, including information to address uncertainty about allergens, may be required to assess possible future applications with reduced limits and controls, such as a larger scale trial or the commercial release of these GMOs. | Section 4 of Chapter 3 of the RARMP indicates that additional data regarding levels of endogenous wheat allergens in the GM wheat may be required to assess a future application for a commercial release or a release with reduced limits and controls. The Regulator has corresponded with the licence holder to invite them to discuss these data requirements with OGTR staff and consider how and when to generate the data. |
| 9 | No issues. Wheat pollen is particularly bad for cross hybridisation and longevity is poor, so the proposed controls are adequate for outbreeding. There doesn’t seem to be any pollen advantage with the gene insertion. It will probably be no more weedy than other wheat varieties, and the allergenic nature is within the threshold of some of the 500K+ wheat varieties.  Suggests use of more modern non-constitutive promoters for transformation, therefore limiting the upregulation of things in seeds that could be avoided. | Noted. |

# Appendix B: Summary of submissions from the public on the consultation RARMP

The Regulator received eight submissions from members of the public on the consultation RARMP. The issues raised in the submissions are summarised in the table below. All issues that related to risks to the health and safety of people and the environment were considered in the context of currently available scientific evidence in finalising the RARMP that formed the basis of the Regulator’s decision to issue the licence.

**Abbreviations: FSANZ:** Food Standards Australia New Zealand; **GM:** genetically modified; **GMO:** genetically modified organism; **OGTR:** Office of the Gene Technology Regulator; **RARMP:** Risk Assessment and Risk Management Plan; **Regulator:** Gene Technology Regulator

| **Submission** | | **Summary of issues raised** | **Comment** |
| --- | --- | --- | --- |
| 1 | If it is not for human or animal use, then what is the prime objective of this trial? | | As discussed in Section 2 of Chapter 1 of the RARMP, the purpose of the field trial is to evaluate the GM wheat under Australian growing conditions, including under environmental stress. The trial will gather research and regulatory data regarding agronomic performance, environmental stress tolerance, nutritional assessment, compositional analysis, molecular analysis, and genetic stability.  The licence holder may use data gathered during this field trial to support a future application for commercial release of the GM wheat. |
| 2 | How do you increase tolerance to environmental stress in GM wheat? | | As discussed in Section 4 of Chapter 1 of the RARMP, the GM wheat contains an introduced gene that increases tolerance to several types of environmental stresses, particularly water stress. The introduced gene comes from sunflower. The introduced gene is expected to help GM wheat plants to survive and provide good yields under unfavourable growing conditions, such as during drought (water stress).  The introduced gene produces a protein called Hahb-4, which works by changing the amounts of other proteins that are naturally present in wheat. It does not change the types of proteins produced by the GM wheat. |
| I am deeply concerned for the future health and safety of my children and grandchildren and of the liveability of the planet they are inheriting. | | Noted. The purpose of the Office of the Gene Technology Regulator (OGTR) is to protect the health and safety of people and the environment from risks posed by gene technology. |
| 3 | Concerned about the potential risk to human health from this trial. Uncertainty about the long-term effects of human consumption and the possibility of unintended consequences, such as allergic reactions or unforeseen health issues among consumers. The lack of conclusive evidence on the safety of GMOs for human consumption warrants caution and thorough investigation before allowing such trials. | | As part of the limits and controls imposed for this field trial, a licence condition prohibits GM plant material or products being used for human food or animal feed. None of the GM wheat from this trial will enter the human food supply.  Food Standards Australia New Zealand (FSANZ) is the Australian Government agency responsible for food safety, including GM food. FSANZ has established a rigorous and transparent process for assessing the safety of GM foods before they are allowed in the food supply. Further information on the regulation and assessment of GM foods is available from the [FSANZ website](https://www.foodstandards.gov.au/consumer/gmfood). |
| The environmental impact of GM crops cannot be overlooked. The potential for cross-contamination with wild or traditional crop varieties raises serious concerns about biodiversity and ecosystem stability. | | As discussed in Section 5.4 of Chapter 1 of the RARMP, the only plant species in the Australian environment that are sexually compatible with the GM wheat are 3 non-native crop plants: bread wheat, durum wheat and triticale. The GM wheat cannot cross-breed with any wild or native plant species in Australia. |
| The spread of GM genes to non-GMO crops could have irreversible consequences, impacting the delicate balance of our local ecosystems. Recognises that effort has been made to limit this spread, however there are environmental factors outside of the study controls that could result in GMO contamination of the area. | | Risk scenario 2 in Chapter 2 of the RARMP considers the potential for pollen flow (spread of genetically modified genes) from the GM wheat to non-GM crops. The risk scenario finds that the field trial controls would minimise pollen flow, and that even if a very low level of pollen flow occurred, the risk to the environment is negligible.  The licence includes a requirement to report any extreme weather affecting an area where GMOs are present. If GMOs have been spread outside field trial sites by extreme weather, the licence holder must implement a contingency plan to recover or destroy the GMOs. |
| Threat to any organic farming in the vicinity. | | The Gene Technology Regulator (the Regulator) is required to assess applications for release of GMOs in accordance with the Act, the object of which is to protect the health and safety of people and the environment. Marketing and trade issues, including organic farming branding, are outside the scope of assessments conducted by the Regulator. These issues are the responsibility of the State and Territory governments and industry. |
| Use of GM crops may lead to increased dependence on specific agrochemicals, posing a threat to beneficial insects, soil health, and water resources. | | As discussed in Section 5.3 of Chapter 1 of the RARMP, the GM wheat will be cultivated using conventional crop management practices for wheat. Agrochemical use during the field trial will be similar to use for a non-GM wheat crop. |
| Notes numerous scientific studies highlighting uncertainties about the long-term environmental and health effects of GMOs. Wants comprehensive and independently verified data demonstrating the safety of GM wheat, before proceeding with trials that could have far-reaching consequences for our community. Essential to prioritise the precautionary principle and exercise due diligence in evaluating the potential risks before exposing our community to uncertainties associated with GM crops. | | The Regulator is an independent statutory office holder who reports directly to the Australian Parliament. Before the Regulator decides whether to issue a licence for release of GMOs, scientists in the Office of the Gene Technology Regulator (OGTR) prepare a RARMP. The RARMP includes a thorough and critical assessment of data supplied by the applicant, together with a comprehensive review of other relevant national and international scientific literature. It considers both short- and long-term risks from the GMOs. The RARMP is finalised following an extensive consultation process involving expert scientists, Australian Government authorities and regulatory agencies, State and Territory Governments, relevant local councils and the public. The RARMP for this application concluded that the proposed field trial of the GM wheat poses negligible risks to the health and safety of people or to the environment. |
| 4 | Requests comprehensive measures to ensure there is no contamination of HB4 in Australian commercial wheat during the trial.  States that insufficient information is provided to determine whether measures to prevent leakage into the external environment during the cultivation trial period are to be fully implemented. Requests further clarification regarding the management and operation methods. Requests that the trial be approved only after confirmation of the measures to prevent leakage.  Examples for clarification: The locations for milling, processing and evaluation tests, type of transport and the routes to these locations, and the disposal of samples after testing. | | As discussed in Section 3.1 of Chapter 3 of the RARMP, stringent licence conditions are imposed to minimise dispersal of HB4 wheat or its pollen outside field trial sites.  The DIR 204 licence requires transport of HB4 wheat in accordance with the Regulator’s [Guidelines for the Transport, Storage and Disposal of GMOs](https://www.ogtr.gov.au/resources/publications/guidelines-transport-storage-and-disposal-gmos). The guidelines include requirements to double-contain the GMOs during transport, label the outer packaging as containing GMOs, and only permit trained staff to access the packages containing GMOs.  The licence requires processing (including milling) or analysis of HB4 wheat to take place in field trial sites or in a facility approved in writing by the Regulator. Currently, the only facilities permitted for processing or analysis of HB4 wheat are specialised laboratories or plant facilities that have been certified by the OGTR as suitable for physical containment of GMOs.  The licence requires HB4 wheat grain that is not needed for experimentation or future planting to be destroyed by one of a list of approved techniques. The licence prohibits disposing of HB4 wheat in any way that would involve it entering food for humans or feed for animals. |
| Requests that the company/business conducting the trial cultivation discloses their operational plans and results every year, including the planned location of the trial field, in order to confirm that their operation and management is being properly implemented. | | Before planting GM wheat at any field trial site, the licence holder must send a planting notification to the OGTR. The location, size and planting date of each field trial site is routinely published on our website. This information will be available on both the [DIR 204](https://www.ogtr.gov.au/gmo-dealings/dealings-involving-intentional-release/dir-204) webpage and the [Crop field trial map](https://www.ogtr.gov.au/what-weve-approved/crop-field-trial-map).  The OGTR’s Monitoring and Compliance Section conduct periodic inspections of field trial sites to ensure compliance with licence conditions. |
| The HB4 wheat is currently not authorised as safe in Japan. If HB4 wheat contaminates commercial wheat, it would be a violation of Japan’s Food Sanitation Act, potentially leading to the suspension of Australian wheat imports and impacting many stakeholders. Therefore, before the trial is approved, we request the development of official testing methods and the establishment of testing systems so that it can be confirmed that Australian wheat for export does not contain HB4 wheat. Requests that this information be disclosed to all relevant stakeholders. | | The DIR 204 licence includes a range of licence conditions to isolate HB4 wheat grown in the field trial from commercial wheat. As discussed in Section 3 of Chapter 3 of the RARMP, these licence conditions are considered effective. Over the last 19 years, the Regulator has issued 24 other licences for field trials of GM wheat in Australia. There have been no reports of presence of GM wheat in Australian commercial wheat for domestic use or export.  The Regulator does not have the power to mandate a testing system for non-GM wheat.  Marketing and trade issues are outside the scope of assessments conducted by the Regulator. These issues are the responsibility of the State and Territory governments and industry. |
| 5 & 6 | (Sub. 5 and 6) The application for field trials in Australia has drawn attention from wheat processors and wheat-based food manufacturers given the prior amendment of Food Standards Australia and New Zealand (FSANZ) Food Standard Code to include drought-tolerant and herbicide-tolerant wheat line IND-00412-7 as a permitted food produced using gene technology.  (Sub. 5 and 6) Labelling provisions (FSANZ) require the foods produced using gene technology to state ‘genetically modified’ in conjunction with the name of the genetically modified food or ingredient.  (Sub. 5 and 6) Considering wheat storage, handling and processing practices in Australia and New Zealand, there is a high likelihood of unintentional presence of GM wheat in non-GM wheat impacting processed wheat, flour or derived ingredients, or manufactured foods. The novel DNA or novel protein would be present, requiring the processed wheat, flour or derived ingredients, or manufactured foods to be labelled as ‘genetically modified’.  (Sub. 5) With more than 90% of the Australian retail market committed to ensure own label foods contain no genetically modified ingredients or additives, unintentional contamination of wheat would limit markets for sale of Australian manufactured wheat-based ingredients and foods and limit choice for Australian shoppers and consumers and restrain trade for Australian grain processors and food manufacturers.  (Sub. 6) Concerned that as the majority of wheat milled in the North Island of New Zealand is sourced from Australia, unintentional contamination of wheat would limit markets for sale of New Zealand manufactured wheat-based ingredients and foods and limit choices for New Zealand shoppers and consumers and minimise trade for New Zealand grain processors and food manufacturers.  (Sub. 5) With the bulk of Australian wheat exported to many international markets throughout Asia and Middle East primarily due to functional properties of Australian wheat and the local market and consumer’s demand for health, wellbeing and sustainable foods and ingredients, contamination with a GM wheat line would be disastrous for the Australian wheat industry. | | The DIR 204 licence authorises a limited and controlled field trial of the GM wheat. The licence includes a range of licence conditions to isolate the GM wheat grown in the field trial from commercial wheat. In addition, a licence condition specifically requires that the GM wheat ‘must not be used, sold or otherwise disposed of for any purpose which would involve or result in its use as food for humans or feed for animals’. As discussed in Section 3 of Chapter 3 of the RARMP, these licence conditions are considered effective. Over the last 19 years, the Gene Technology Regulator has issued 24 other licences for field trials of GM wheat in Australia. There have been no reports of presence of GM wheat in Australian commercial wheat for domestic use or export.  Marketing and trade issues are outside the scope of assessments conducted by the Regulator. These issues are the responsibility of the State and Territory governments and industry. |
|  | (Sub. 5 and 6) The Regulator needs to consider ambiguity of consumer sentiment in Australia and New Zealand towards genetically modified ingredients and foods before proceeding with approval of the licence application for field trials, and potential commercialization of wheat line IND‑00412-7. | | The Regulator is required to assess GMO applications in accordance with the Act, the object of which is to protect the health and safety of people and the environment. Consumer preferences and attitudes are outside the scope of assessments conducted by the Regulator. |
|  | (Sub. 5 and 6) Urges the Regulator to adopt tighter controls of the field trials, specifically discrete segregation of the GM wheat line during harvest, processing and evaluation. Requests industry certified testing of standard wheat for novel DNA or protein, and publicly available reporting to show the absence of genetically modified material, as a transparent case study of handling, storage and processing, prior to potential commercialization. | | The DIR 204 licence includes strict controls on harvesting, processing and evaluation of the GM wheat. The GM wheat must be harvested separately from any other crop, and equipment used with the GM wheat must be cleaned prior to use for any other purpose. Processing and analysis of the GM wheat may only be undertaken in a field trial site or in a facility approved by the Regulator. Currently, the only facilities permitted for processing or analysis of HB4 wheat are specialised laboratories or plant facilities that have been certified by the OGTR as suitable for physical containment of GMOs.  The Regulator does not have the power to mandate testing of non-GM wheat. |
| 7 | Appreciates various licence conditions to prevent contamination of commercial wheat are spelled out in the DIR 204 RARMP, whose validity we hope will be scrutinised by relevant scientists. | | The DIR 204 RARMP was prepared by scientists in the OGTR. As part of the consultation process, the RARMP was also reviewed by expert scientists on Australia’s Gene Technology Technical Advisory Committee, as well as a range of government agencies. |
| In order to ensure that these conditions are complied with by those who actually conduct test cultivation, we request all the notifications, reports and documentation listed in “Section 5 Reporting and documentation” in the DIR 204 licence will be disclosed upon request. | | All reports, notifications and documentation submitted in accordance with the DIR 204 licence will be scrutinised by the OGTR’s Monitoring and Compliance Section. Staff from the Monitoring and Compliance Section also conduct periodic inspections of field trial sites. Any non‑compliances with licence conditions, along with actions taken to rectify the issues, are reported in the OGTR’s Annual Reports which are published on the [OGTR website](https://www.ogtr.gov.au/resources).  Any report, notification or documentation that is submitted to the OGTR can also be requested under the Australian Government’s Freedom of Information (FOI) provisions. |
| Since HB4 wheat is currently not authorised as safe in Japan, if HB4 wheat were to contaminate commercial wheat, it would be a violation of Japan’s Food Sanitation Act and would result in suspension of Australian wheat imports to Japan which would then affect many stakeholders.  Requests official inspection method be developed, and an inspection & operation system be established before the trial cultivation of HB4 wheat is approved, to confirm that HB4 wheat is not included in any Australian commercial wheat exports.  Requests that the information on the inspection methods, including those referred to in para 180 of the DIR 204 RARMP be disclosed to relevant stakeholders, and requests that samples of HB4 wheat will be available to the governments of countries importing Australian wheat on request. | | The DIR 204 licence includes a range of licence conditions to isolate HB4 wheat grown in the field trial from commercial wheat. In addition, a licence condition specifically requires that the GM wheat ‘must not be used, sold or otherwise disposed of for any purpose which would involve or result in its use as food for humans or feed for animals’. As discussed in Section 3 of Chapter 3 of the RARMP, these licence conditions are considered effective. Over the last 19 years, the Gene Technology Regulator has issued 24 other licences for field trials of GM wheat in Australia. There have been no reports of presence of GM wheat in Australian commercial wheat for domestic use or export.  The Regulator does not have the power to mandate an inspection system for non-GM wheat.  Marketing and trade issues are outside the scope of assessments conducted by the Regulator. These issues are the responsibility of the State and Territory governments and industry.  A detection method for HB4 wheat was supplied in the licence application. This method can be obtained by requesting a copy of the DIR 204 licence application from the OGTR. The licence holder or the developer of HB4 wheat could be contacted directly to request further information regarding inspection methods or to request seed samples. |
| 8 | Supports grain producers having the choice to access and adopt appropriate new technologies, including crop biotechnology in farming systems, to manage their farming systems sustainably and profitably. Access should be based on these varieties having been assessed and approved by an independent, science-based Australian regulator.  Recognises the GM wheat is intended to address current climatic challenges to industry.  Support for the Office of the Gene Technology Regulator as the body responsible for ensuring that research trials and commercial releases be strictly contained within the legislated guidelines.  Aware of the challenges and concerns regarding GM cereal crops and understands the intent of the scientific research and evaluation processes which are the subject of this application to the OGTR. In the absence of any further information or evidence on these matters, we support this application in principle to establish scientific evidence and look forward to the results of the OGTR’s assessment.  Note there are other approvals needed, with respect to the future commercialisation of HB4 Wheat and reserve judgement on this potential variety, subject to further research and evidence, particularly economic impacts and market acceptance in Australian and global grain export and consumer markets.  Engaged other stakeholders and they also support the process of crops being approved based on Australia’s strong regulatory framework for gene technology and rigorous scientific assessment. Recognises that any uptake of HB4 Wheat will be determined by the market and what delivers best value to growers. One stakeholder indicated support for choice in relation to biotechnology provided that choice respects the rights of others to also choose. Another stakeholder commented on the importance of communication about biotechnology. | | Noted. |

1. The physiological development of a plant can be measured in degree-days, which is a means of combining time and temperature into a single number. Degree-days in wheat have been calculated as the sum of the average daily temperature, minus the minimum temperature at which the plant grows, over consecutive days ([Bowden et al., 2008](#_ENREF_5)). [↑](#footnote-ref-1)
2. Prescribed expects, agencies and authorities include GTTAC, State and Territory Governments, Australian Government agencies and the Minister for the Environment. [↑](#footnote-ref-2)